

CURRICULUM VITAE

Henry S. Park, M.D., M.P.H.
Professor of Therapeutic Radiology
Vice Chair for Clinical Research, Health Services Research, and Faculty Development
Assistant Dean for Admissions
Head of Horstmann Advisory House
Yale School of Medicine

Version Date: August 4, 2026

Education:

08/2003-05/2007	BS, Music and Molecular, Cellular, and Developmental Biology (Neurobiology), Yale College, New Haven, CT
08/2007-05/2012	MD, <i>cum laude</i> , Yale School of Medicine, New Haven, CT
08/2011-05/2012	MPH, Quantitative Methods, Harvard School of Public Health, Boston, MA
09/2024-06/2025	Healthcare Leadership Program (non-degree), Yale School of Medicine and Yale New Haven Hospital System, New Haven, CT

Career/Academic Appointments:

06/2012-06/2013	Intern, Internal Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
06/2013-06/2017	Resident, Radiation Oncology Yale New Haven Hospital, Yale School of Medicine, New Haven, CT
06/2016-06/2017	Chief Resident, Radiation Oncology Yale New Haven Hospital, Yale School of Medicine, New Haven, CT
07/2017-06/2018	Assistant Clinical Professor of Therapeutic Radiology Yale School of Medicine, New Haven, CT
07/2018-06/2022	Assistant Professor of Therapeutic Radiology Yale School of Medicine, New Haven, CT
07/2022-06/2025	Associate Professor of Therapeutic Radiology Yale School of Medicine, New Haven, CT
07/2025-present	Professor of Therapeutic Radiology Yale School of Medicine, New Haven, CT

Administrative Positions:

07/2017-02/2023	Director, Medical Student Clerkship in Radiation Oncology Yale School of Medicine, New Haven, CT
07/2017-07/2022	Director, Continuing Medical Education in Radiation Oncology Yale School of Medicine, New Haven, CT
07/2017-06/2022	Director, Yale Radiation Oncology Consortium Yale School of Medicine, New Haven, CT
07/2018-11/2022	Associate Director, Radiation Oncology Residency Program Yale School of Medicine, New Haven, CT
11/2019-present	Chief, Thoracic Radiotherapy Program Yale School of Medicine, New Haven, CT
10/2021-09/2023	Leader, Therapeutic Radiology Clinical Research Team Yale Cancer Center, New Haven, CT
07/2022-12/2025	Vice Chair for Clinical Research, Therapeutic Radiology Yale School of Medicine, New Haven, CT
07/2022-06/2025	Director, Yale Radiation Oncology Course for Clinical Research Yale School of Medicine, New Haven, CT
07/2023-present	Leader, Radiation Oncology Committee Yale Cancer Center, New Haven, CT

07/2023-present	Associate Leader, Lung Clinical Research Team Yale Cancer Center, New Haven, CT
08/2023-present	Head of Advisory House, Horstmann House Yale School of Medicine, New Haven, CT
12/2023-present	Assistant Medical Director, Clinical Trials Office Yale Cancer Center, New Haven, CT
07/2024-present	Chief, PET-Guided Radiotherapy Program Yale School of Medicine, New Haven, CT
01/2026-present	Vice Chair for Clinical Research, Health Services Research, and Faculty Development, Therapeutic Radiology Yale School of Medicine, New Haven, CT
02/2026-present	Workshop Leader, Populations & Methods Longitudinal Course: The Application of Epidemiology and Biostatistics to Public Health Yale School of Medicine, New Haven, CT
07/2026-present	Assistant Dean for Admissions Yale School of Medicine, New Haven, CT

Board Certification:

American Board of Radiology, Radiation Oncology, 2018

Professional Honors & Recognition:

International/National/Regional

- 2011 Young Oncologist Essay Award, American Radium Society (ARS)
- 2012 Travel Grant, American Radium Society (ARS)
- 2014 Resident/Fellow Travel Grant, Korean American Society of Radiation Oncology (KASTRO)
- 2014 Travel Grant, American Radium Society (ARS)
- 2015 Resident Digital Poster Recognition Award (Clinical), American Society for Radiation Oncology (ASTRO)
- 2015 Resident/Fellow Travel Grant, Korean Society for Radiation Oncology (KOSRO)
- 2015 Young Investigator Award, International Gamma Knife Research Foundation (IGKRF)
- 2016 Resident Poster Viewing Recognition Award (Clinical), American Society for Radiation Oncology (ASTRO)
- 2017 Roentgen Resident/Fellow Research Award, Radiographic Society of North America (RSNA) R&E Foundation
- 2018 Outstanding Reviewer Award, *International Journal of Radiation Oncology, Biology Physics* (Red Journal)
- 2019 Outstanding Reviewer Award, *Advances in Radiation Oncology*
- 2019 (As mentor to award recipient Dr. Vikram Jairam) Annual Meeting Merit Award, Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO)
- 2020 Outstanding Reviewer Award, *International Journal of Radiation Oncology, Biology, Physics* (Red Journal)
- 2020 Reviewer of the Month, *Journal of Thoracic Disease*
- 2020 (As mentor to award recipient Dr. Vikram Jairam) Pain and Symptom Management Special Merit Award, Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO)
- 2020 (As co-mentor to award recipient Dr. Ranjan Pathak) Annual Meeting Merit Award, Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO)
- 2020 (As mentor to award recipient Nadia Saeed) Travel Grant, American Radium Society (ARS)
- 2022 Outstanding Reviewer Award, *International Journal of Radiation Oncology, Biology, Physics* (Red Journal)
- 2022 Educator of the Year Award, Association of Residents in Radiation Oncology (ARRO)
- 2023 (As mentor to award recipient Catherine Lerro) Spotlight Poster Winner, International Conference on Pharmacoepidemiology (ICPE)
- 2023 Outstanding Reviewer Award, *Advances in Radiation Oncology*

2024 Outstanding Reviewer Award, *Practical Radiation Oncology*
2024 Outstanding Reviewer Award, *Advances in Radiation Oncology*
2025 Modality and Discipline Travel Support Program Award, SWOG Cancer Research Network
2025 (As mentor to award recipient Victor Lee) Annual Meeting Abstract Award, American Society for Radiation Oncology (ASTRO)
2025 Top Reviewer Award, *Journal of the National Cancer Institute*
2026 Most Cited Paper Award, *Translational Lung Cancer Research*

University

2008 Paul H. Lavietes, M.D. Medical Student Summer Research Fellowship, Yale School of Medicine
2010 James G. Hirsch, M.D. Endowed Medical Student Research Fellowship, Yale School of Medicine
2011 William U. Gardner Memorial Medical Student One-Year Research Fellowship, Yale School of Medicine
2012 American Cancer Society Prize, Yale School of Medicine
2012 Frank Parker Prize, Yale School of Medicine
2012 Commencement M.D. Student Marshal, Yale School of Medicine
2019 (As mentor to award recipient Dr. Nicholas Lee), Cancer Prize, Yale School of Medicine
2021 Clinician of the Year, Department of Therapeutic Radiology, Yale School of Medicine

Grant/Clinical Trials History:

Current Grants

Agency: National Cancer Institute
I.D.# UG1CA233337
Title: Yale Cancer Center NTCN LAPS
Role: NRG Oncology Contact Principal Investigator since 1/1/22 (PI: Chiang)
Percent effort: 0%
Total costs: \$5,958,699
Project period: 3/8/19-2/28/27

Agency: National Institute on Minority Health and Health Disparities (NIMHD)
I.D.# R01MD017569
Title: Factors associated with high quality care for patients with lung cancer
Role: Advisory Board Member (PI: Gross)
Percent effort: 0%
Total costs: \$2,547,019
Project period: 9/21/22 – 5/31/27

Agency: National Cancer Institute (NCI)
I.D.# R01CA304967
Title: Development and clinical translation of advanced PET imaging for real-time biology-guided radiotherapy
Role: Multiple Principal Investigator (Contact PI: Liu, MPI: Carlson, Feghali, Park)
Percent effort: 10%
Total costs: \$2,942,785
Project period: 6/25/26 – 5/31/31

Past Grants

Agency: Food and Drug Administration (FDA) Center of Excellence in Regulatory Science and Innovation (CERSI) to Yale University and Mayo Clinic
I.D.# U01FD005938 (FDA)
Title: Trends in opioid use among patients with cancer
Role: Principal Investigator (PI: Park)
Percent effort: 10%

Total costs: \$369,769.00
Project period: 9/1/21 – 8/31/24

Agency: Yale Cancer Center
I.D.# N/A
Title: Disparities in stereotactic radiosurgery access for brain metastases from non-small cell lung cancer and breast cancer
Role: Principal Investigator (PI: Park)
Percent effort: 5%
Total costs: \$65,000.00
Project period: 8/1/23 – 1/31/25

Agency: RefleXion Medical
I.D.# N/A
Title: Complete vs incomplete consolidative radiotherapy in patients with oligometastatic extensive-stage small cell lung cancer
Role: Principal Investigator (PI: Park)
Percent effort: 1%
Total costs: \$16,000.00
Project period: 1/17/24 – 1/16/25

Agency: RefleXion Medical
I.D.# N/A
Title: Concordance of PET-guided functional modeling, diagnostic PET-guided, and 4D CT-based tumor delineation for lung tumors
Role: Principal Investigator (PI: Park)
Percent effort: 1%
Total costs: \$14,000.00
Project period: 1/17/24 – 1/16/25

Current Clinical Trials

Agency: Yale Department of Therapeutic Radiology
I.D.# IRB #2000024722
Title: DD3: Phase I/II trial of dose-deescalated 3-fraction SBRT for centrally located lung cancer
Role: Principal Investigator
Percent effort: 0%
Total costs: \$0
Project period: 3/9/20 – Ongoing

Agency: NRG Oncology
I.D.# IRB #1412015097
Title: NRG-LU007: Randomized phase II/III trial of consolidation radiation + immunotherapy for ES-SCLC (RAPTOR)
Role: SWOG Study Champion, Institutional Principal Investigator
Percent effort: 0%
Total costs: \$0
Project period: 7/11/20 – Ongoing

Agency: Johnson & Johnson Enterprise Innovation, Inc.
I.D.# IRB #2000040874
Title: CONVERGE: A phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer

Role: SWOG Study Champion, Institutional Principal Investigator
Percent effort: 0%
Total costs: \$0
Project period: 3/20/26 – Ongoing

Past Clinical Trials

Agency: NRG Oncology
I.D.# IRB #1412015097
Title: NRG-HN001: Randomized phase II and phase III studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein Barr virus (EBV) deoxyribonucleic acid (DNA)
Role: Institutional Principal Investigator
Percent effort: 0%
Total costs: \$0
Project period: 11/12/18 – 7/18/23

Agency: SWOG Cancer Research Network
I.D.# IRB #2000027403
Title: S1827: Randomized phase III trial of MRI surveillance with or without prophylactic cranial irradiation (PCI) in small-cell lung cancer
Role: Institutional Principal Investigator
Percent effort: 0%
Total costs: \$0
Project period: 1/14/21 – 12/15/25

Agency: Merck
I.D.# IRB #2000025217
Title: KEYNOTE-867: A phase 3, randomized, placebo-controlled clinical study to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) with or without pembrolizumab (MK-3475) in participants with medically inoperable stages I or IIA non-small cell lung cancer (NSCLC)
Role: Institutional Principal Investigator
Percent effort: 0%
Total costs: \$0
Project period: 10/4/21 – 12/7/23

Agency: SWOG Cancer Research Network
I.D.# IRB #2000030031
Title: S1914: A randomized phase III trial of induction/consolidation atezolizumab (NSC #783608) + SBRT versus SBRT alone in high risk, early stage NSCLC
Role: Institutional Principal Investigator
Percent effort: 0%
Total costs: \$0
Project period: 2/7/22 – 9/6/24

Agency: RefleXion Medical
I.D.# IRB #2000034887
Title: PREMIER: Prospective data registry and quality of life assessment of patients undergoing radiotherapy with the RefleXion Medical radiotherapy system
Role: Institutional Principal Investigator
Percent effort: 0%
Total costs: \$0
Project period: 1/12/24 – 10/10/25

Past Training Grants

Agency: National Institutes of Health / National Heart, Lung, and Blood Institute
I.D.# T35HL007649
Title: Clinical impact of integrated concurrent chemoradiation therapy at a single facility for lung cancer patients
Trainee: Yesung Lee, B.S.
Total costs: \$6,204
Project period: 6/16/19 – 9/15/19

Agency: Yale School of Medicine
I.D.# Richard K. Gershon Medical Student Fellowship; Jane Danowski Weiss Family Foundation Fellowship; James G. Hirsch Endowed Medical Student Research Fellowship; Yale School of Medical Student Fellowship
Title: Nationwide patterns of hemorrhagic stroke among patients hospitalized with brain metastases: influence of primary cancer diagnosis and anticoagulation
Trainee: Victor Lee, B.S.
Role: Faculty Sponsor
Total costs: \$41,774
Project period: 3/1/20 – 11/30/21

Agency: National Institutes of Health / National Heart, Lung, and Blood Institute
I.D.# T35HL007649
Title: Comparison of effectiveness and toxicity of high-dose hypofractionated radiotherapy to conventionally fractionated radiotherapy or stereotactic body radiotherapy in stage I-II non-small cell lung cancer patients treated at Yale New Haven Hospital
Trainee: Alexander Sasse, B.S.
Role: Faculty Sponsor
Total costs: \$11,820
Project period: 6/16/20 – 9/15/20, 9/1/22 – 11/30/22

Agency: National Institutes of Health / National Heart, Lung, and Blood Institute
I.D.# T35HL007649
Title: National trends in local therapy of lung metastases from head and neck cancer
Trainee: Amrita Singh, B.A.
Role: Faculty Sponsor
Total costs: \$6,330
Project period: 6/16/20 – 9/15/20

Agency: Yale School of Medicine
I.D.# William U. Gardner Memorial Student Research Fellowship; Yale Medical Student Fellowship
Title: Utilization and survival impact of high-dose hypofractionated radiotherapy compared to stereotactic body radiotherapy in inoperable stage I non-small cell lung cancer
Trainee: Nadia Saeed, B.S.
Role: Faculty Sponsor
Total costs: \$3,164
Project period: 7/14/20 – 12/31/20

Agency: Yale School of Medicine
I.D.# Richard K. Gershon Medical Student Fellowship
Title: Utilization of HFRT vs SBRT in NSCLC: retrospective study and detailed dosimetric analysis

Trainee: Alexander Sasse, B.S.
Role: Faculty Sponsor
Total costs: \$6,588
Project period: 12/1/22 – 2/28/23

Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale:

1. “A decade of changing practice patterns for LINAC SRS vs. Gamma Knife SRS for brain metastases in the U.S.” Invited Speaker for Varian Symposium, Radiosurgery Society (RSS) Annual Scientific Meeting, Orlando, FL, 2016.
2. “Updated national trends in LINAC radiosurgery for brain metastases.” Invited Speaker for Varian Symposium, Radiosurgery Society (RSS) Annual Scientific Meeting, Orlando, FL, 2016.
3. “Lung / Pediatric scientific session.” Moderator, 101st American Radium Society (ARS) Annual Meeting, Dana Point, CA, 2019.
4. “Stage III non-small cell lung cancer / combined modality therapy.” Session Chair, International Association for the Study of Lung Cancer (IASLC) Targeted Therapies of Lung Cancer (TTLC) Meeting, Santa Monica, CA, 2020.
5. “Lung malignancies.” Panelist, Radiation Oncology Virtual Education Rotation (ROVER): Multi-Institutional Teaching Session, Virtual Event, 2020.
6. “Multidisciplinary management of thoracic cancer during COVID-19.” Panelist, American College of Surgeons (ACS) Webinar, Virtual Event, 2020.
7. “Overcoming barriers to radiation oncology access in low-resource environments.” Moderator, 62nd American Society for Radiation Oncology (ASTRO) Annual Meeting. Virtual Meeting, 2020.
8. “Global oncology and health disparities.” Moderator, American Society for Radiation Oncology (ASTRO) Annual Meeting, Virtual Meeting, 2020.
9. “Stage III non-small cell lung cancer / combined modality therapy.” Panelist, International Association for the Study of Lung Cancer (IASLC) Targeted Therapies of Lung Cancer (TTLC) Meeting. Virtual Meeting, 2021.
10. “Current and future advances in managing esophageal cancer.” Invited Grand Rounds Speaker, Cancer Treatment Centers of America (CTCA), sponsored by an educational grant by Bristol Myers Squibb. Virtual Event, 2021.
11. “Emerging lung cancer data.” Panelist, AstraZeneca Lung Cancer Fireside Chat – New York / New England. Virtual Event, 2021.
12. “The role of stereotactic radiotherapy in operable early-stage NSCLC.” Invited Speaker, Advances in The Management of Thoracic Malignancies. Hosted by Alfaisal University, Riyadh, Kingdom of Saudi Arabia. Virtual Meeting, 2021.
13. “Immunotherapy and radiation: considerations on outcomes and toxicity in lung cancer.” Invited Speaker, Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy (ACI): A Focus on Lung Cancer. Virtual Event, 2022.
14. “Surgery and immunotherapy-based neoadjuvant therapy in the management of operable stage III NSCLC.” Speaker, SWOG Lung Disease Working Group Meeting and SWOG Lung Radiation and Surgery Subcommittee Meeting, Seattle, WA, 2022.
15. “Ablation of early-stage larynx cancer with intensity-modulated radiotherapy for carotid-sparing effect.” Speaker, ECOG-ACRIN Radiation Committee and Head and Neck Core Committee Meetings, Chicago, IL, 2022.
16. “Surgery or radiotherapy with neoadjuvant vs. adjuvant immunotherapy-based treatment for stage III NSCLC.” Invited Speaker, SWOG Lung Disease Working Group Meeting and SWOG Lung Radiation and Surgery Subcommittee Meeting, Chicago, IL, 2022.
17. “New directions for HPV-associated (and HPV-negative) squamous cell carcinoma.” Moderator, 64th American Society for Radiation Oncology (ASTRO) Annual Meeting, San Antonio, TX, 2022.
18. “Management of p16+ unknown primary of the head and neck.” Invited Speaker, 64th American Society for Radiation Oncology (ASTRO) Annual Meeting, San Antonio, TX, 2022.
19. “Arytenoid-sparing whole-larynx intensity-modulated vs. 3D conformal radiotherapy for early-stage glottic cancer.” Speaker, ECOG-ACRIN Radiation Committee and Head and Neck Core Committee Meetings, Washington, DC, 2022.

20. “Multidisciplinary approach to lung cancer patient care.” Panelist, RT Answers: Ask a Radiation Oncologist, American Society for Radiation Oncology (ASTRO) in partnership with CancerGRACE, Virtual Event, 2022.
21. “Locally advanced non-small cell lung cancer.” Panelist, Curio Sciences, Virtual Event, 2022.
22. “ESMO and ASCO updates in non-small cell lung cancer.” Panelist, AstraZeneca Lung Cancer Fireside Chat – New York / New England, Virtual Event, 2022.
23. “Selection, sequencing, and tolerability in small cell lung cancer.” Invited Speaker, i3 Health, sponsored by an educational grant by G1 Therapeutics, Virtual Event, 2022.
24. “Optimizing the role of radiation therapy in oligometastatic NSCLC.” Invited Speaker, Advances in The Management of Thoracic Malignancies. Hosted by Alfaisal University, Riyadh, Kingdom of Saudi Arabia, Virtual Event, 2022.
25. “Real world evidence and clinical trials in lung cancer: conflicting or complementary?” Distinguished Visiting Professor Lecture Invited Speaker, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, Virtual Event, 2023.
26. “Oligometastatic disease.” Invited Speaker, American Society of Clinical Oncology (ASCO) Advantage, sponsored by Daichii Sankyo, Alexandria, VA, 2023.
27. “Sequencing of immunotherapy and chemotherapy in unresectable stage III non-small cell lung cancer.” Acting Chair and Invited Speaker, SWOG Lung Radiation and Surgery Subcommittee Meeting, Lung Committee Meeting, San Francisco, CA, 2023.
28. “Comparison of pathologic outcomes following neoadjuvant regimens in resectable locally advanced non-small cell lung cancer.” Invited Speaker, Flatiron Health Academic Research Oversight Committee Annual Meeting, Chicago, IL, 2023.
29. “How to write an abstract or manuscript.” Invited Speaker, American Society for Radiation Oncology (ASTRO) Medical Student Fellowship Award for Underrepresented Populations Summer Webinar Series, Virtual Event, 2023.
30. “Immune checkpoint inhibition (ICI): incorporation into SCLC management; impacts on toxicity for LA-NSCLC.” Moderator, 65th American Society for Radiation Oncology (ASTRO) Annual Meeting, San Diego, CA, 2023.
31. “Trends in opioid use among patients with cancer.” Invited Speaker, Food and Drug Administration (FDA) Office of Regulatory Science and Innovation (ORSI), Centers of Excellence in Regulatory Science and Innovation (CERSI) Program Showcase, Virtual Event, 2023.
32. “Sequencing of immunotherapy and chemoradiotherapy in unresectable stage III non-small cell lung cancer.” Invited Speaker, SWOG Lung Disease Working Group Meeting and SWOG Lung Radiation and Surgery Subcommittee Meeting, Chicago, IL, 2023.
33. “Converting unresectability to resectability with neoadjuvant therapy in stage III non-small cell lung cancer.” Invited Speaker, SWOG Lung Radiation and Surgery Subcommittee Meeting, Chicago, IL, 2023.
34. “Modern multidisciplinary management of locally advanced non-small cell lung cancer.” Visiting Professor Grand Rounds Invited Speaker, Kaiser Permanente Los Angeles Medical Center and Kaiser Permanente Bernard J. Tyson School of Medicine, Virtual Event, 2024.
35. “Yale patient cases of biology-guided radiotherapy.” Speaker, Cross-Site Workshop, RefleXion Medical, Virtual Event, 2024.
36. “Sequencing of immunotherapy and chemoradiotherapy in unresectable stage III non-small cell lung cancer.” Speaker, SWOG Lung Radiation and Surgery Subcommittee Meeting, Seattle, WA, 2024.
37. “Medically operable locally advanced non-small cell lung cancer.” Invited Speaker, 106th American Radium Society (ARS) Annual Meeting, Palm Springs, CA, 2024.
38. “Optimizing treatment of locally advanced non-small cell lung cancer: a multimodal approach in the immunotherapy era: radiation oncologist perspective.” Invited Speaker, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
39. “Health disparities.” Session Chair, National Cancer Institute Translational Research Program, Annual Lung Cancer SPORE Workshop, New Haven, CT, 2024.
40. “Yale’s early SCINTIX therapy experience.” Speaker, RefleXion Medical. New York, NY, 2024.
41. “How to write an abstract or manuscript.” Speaker, American Society for Radiation Oncology (ASTRO) Medical Student Fellowship Award Summer Webinar Series, Virtual Event, 2024.

42. “Limited-stage small cell lung cancer.” Moderator, AstraZeneca “Lung Unlimited” Scientific Exchange Meeting, San Diego, CA, 2024.
43. “Trial design in the early-stage space: concerns and controversies.” Session Chair, World Conference on Lung Cancer (WCLC), San Diego, CA, 2024.
44. “Multi-target treatment with SCINTIX: the world’s first experience.” Speaker, Cross-Site Workshop, RefleXion Medical, Washington, DC, 2024.
45. “Clinical case reviews.” Speaker and Panelist, RefleXion Experience, RefleXion Medical, Washington, DC, 2024.
46. “The Yale experience with SCINTIX and multi-target treatment.” Speaker, RefleXion Booth, 66th American Society for Radiation Oncology (ASTRO) Annual Meeting, Washington, DC, 2024.
47. “Translational advances in non-small cell lung cancer and prostate cancer.” Educational Session Chair, Korean American Society for Radiation Oncology (KASTRO), Washington, DC, 2024.
48. “SWOG S2509: Sequencing of immunotherapy and chemoradiotherapy in unresectable stage III non-small cell lung cancer.” Speaker, SWOG Lung Disease Working Group Meeting and SWOG Lung Radiation and Surgery Subcommittee Meeting, Chicago, IL, 2024.
49. “Definitive radiotherapy for central or ultra-central stage I non-small cell lung cancer.” Speaker, International Stereotactic Radiosurgery Society (ISRS), Virtual Webinar, 2024.
50. “How to write an abstract or manuscript.” Speaker, American Society for Radiation Oncology (ASTRO) Medical Student Fellowship Award Summer Webinar Series, Virtual Event, 2025.
51. “Sex as a biological variable in radiation oncology: clinical perspective in small cell lung cancer.” Invited Speaker, Trinity College Dublin, Virtual Webinar, 2025.
52. “New directions in lung cancer radiotherapy clinical research.” Visiting Professor Invited Speaker, Trinity College Dublin, Dublin, Ireland, 2025.
53. “Sequencing of immunotherapy and chemoradiotherapy in unresectable stage III non-small cell lung cancer.” Speaker, SWOG Lung Disease Working Group Meeting, Chicago, IL, 2025.
54. “Case study in SCINTIX delivery interruptions.” Speaker, Cross-Site Workshop, RefleXion Medical, San Francisco, CA, 2025.
55. “Longitudinal quality-of-life and immunologic analyses in prostate cancer and cervical cancer.” Educational Session Chair, Korean American Society for Radiation Oncology (KASTRO) Annual Meeting, San Francisco, CA, 2025.
56. “Targeted therapies: ALK, ROS, RET, NTRK, NRG1.” Panelist, International Association for the Study of Lung Cancer (IASLC) Targeted Therapies of Lung Cancer (TTLC) Meeting, Huntington Beach, CA, 2026.
57. “Evolution of stage III non-small cell lung cancer management in the era of immunotherapy and targeted therapy.” Visiting Professor Invited Speaker, University of Florida, Gainesville, FL, 2026.
58. “Education session: thoracic.” Moderator, 108th American Radium Society (ARS) Annual Meeting, Newport Beach, CA, 2026.
59. “The MD-Plus: expanding the physician’s toolkit.” Panelist, 108th American Radium Society (ARS) Annual Meeting, Newport Beach, CA, 2026.
60. “SWOG S2608: Sequencing of immunotherapy and chemoradiotherapy in unresectable stage III non-small cell lung cancer.” Speaker, SWOG Lung Disease Working Group Meeting and SWOG Lung Radiation and Surgery Subcommittee Meeting, San Francisco, CA, 2026.
61. “Optimizing immune checkpoint therapy in nonoperative therapy for NSCLC.” Invited Speaker, Summit on Thoracic Malignancies, DAVA Oncology, Kona, HI, 2026.
62. “Biology-guided radiation therapy for lung cancer.” Invited Speaker, Summit on Thoracic Malignancies, DAVA Oncology, Kona, HI, 2026.
63. “Background and clinical implementation of biology-guided radiation therapy.” Invited Speaker, American College of Radiology, Virtual Webinar, 2026.
64. “How to write an abstract or manuscript.” Speaker, American Society for Radiation Oncology (ASTRO) Medical Student Fellowship Award Summer Webinar Series, Virtual Event, 2025.
65. “Promising or premature? Making sense of randomized phase II trials in radiation oncology.” Invited Speaker, 68th American Society for Radiation Oncology (ASTRO) Annual Meeting, Boston, MA, 2026.

66. “Early stage and locally advanced NSCLC.” Moderator, 68th American Society for Radiation Oncology (ASTRO) Annual Meeting, Boston, MA, 2026.
67. “Updates in lung cancer: stage III non-small cell lung cancer.” Invited Speaker, Fall Foliage Cancer Conference, Continuing Cancer Education, Inc., Asheville, NC, 2026.

Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated With Yale:

1. “Elderly patients receive less aggressive treatment with surgery and radioactive iodine for differentiated thyroid cancer.” Oral/Poster presentation, 30th Annual Meeting of the American Association of Endocrine Surgeons (AAES), Madison, WI, 2009.
2. “A new paradigm in the interpretation of observational studies evaluating postoperative radiation therapy.” Oral presentation, 93rd Annual Meeting of the American Radium Society (ARS), West Palm Beach, FL, 2011.
3. “Treatment and planning efficiency of the Leksell Gamma Knife Perfexion vs. 4C for multiple brain metastases.” Oral presentation, 1st North American Gamma Knife Consortium (NAGKC) Meeting, Pittsburgh, PA, 2011.
4. “Primary urethral cancer: treatment patterns in the U.S.” Oral/Poster presentation, 106th Annual Meeting of the American Urological Association (AUA), Washington, DC, 2011.
5. “Prophylactic cranial irradiation for high-risk patients with locally advanced non-small cell lung cancer.” Poster presentation, 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO), Miami, FL, 2011.
6. “Have national radiotherapy patterns and survival outcomes for skull base chordoma and chondrosarcoma changed over time?” Oral presentation, 94th Annual Meeting of the American Radium Society (ARS), Las Vegas, NV, 2011.
7. “Perioperative outcomes following thymoma surgery: effect of hospital operative volume in the National Inpatient Sample.” Oral presentation, 2nd Annual Meeting of the International Thymic Malignancy Interest Group (ITMIG), Amsterdam, Netherlands, 2011.
8. “Impact of hospital operative volume of video-assisted thoracoscopic lobectomy on perioperative outcomes for primary lung cancer.” Oral presentation, 14th Biennial World Conference on Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC), Amsterdam, Netherlands, 2011.
9. “Pediatric myxopapillary ependymoma: utilization of radiation therapy in the U.S.” Oral/Poster presentation, 4th Biennial Meeting of the Pediatric Radiation Oncology Society (PROS), Venice, Italy, 2011.
10. “Skull base chordoma and chondrosarcoma: an update of national radiotherapy patterns and survival outcomes in the modern era.” Poster presentation, 54th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Boston, MA, 2012.
11. “Central vs. peripheral tumor location: influence on survival, local control, and toxicity following stereotactic body radiotherapy for primary non-small cell lung cancer.” Oral presentation, 96th Annual Meeting of the American Radium Society (ARS), St. Thomas, U.S. Virgin Islands, 2014.
12. “Effect of primary treatment modality on the association between statins and prostate cancer recurrence: an updated meta-analysis.” Poster presentation, 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Francisco, CA, 2014.
13. “Predictors of vaginal stenosis following intravaginal high-dose-rate brachytherapy for endometrial carcinoma.” Oral presentation, 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Francisco, CA, 2014.
14. “Does central vs. peripheral tumor location impact outcomes following stereotactic body radiotherapy for non-small cell lung cancer?” Oral presentation, 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Francisco, CA, 2014.
15. “Spine stereotactic radiosurgery outcomes in patients with concurrent brain metastases.” Oral presentation, 12th Biennial Congress of the International Stereotactic Radiosurgery (ISRS), Yokohama, Japan, 2015.
16. “Changing patterns of Gamma Knife versus linear accelerator-based stereotactic radiosurgery for brain metastases in the United States.” Oral presentation, 12th Biennial Congress of the International Stereotactic Radiosurgery (ISRS), Yokohama, Japan, 2015.

17. "Survival comparison of 3 vs. 4-5 fractions for stereotactic body radiotherapy in stage I non-small cell lung cancer." Oral presentation, 33rd Annual Meeting of the Korean Society for Radiation Oncology (KOSRO), Seoul, South Korea, 2015.
18. "Survival comparison of 3 vs. 4-5 fractions for stereotactic body radiotherapy in stage I non-small cell lung cancer." Oral presentation, 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Antonio, TX, 2015.
19. "Higher annual facility case volume of stereotactic body radiotherapy is associated with improved overall survival in clinical stage I non-small cell lung cancer." Oral presentation, 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Antonio, TX, 2015.
20. "Pediatric brainstem glioma survival after definitive radiotherapy with or without concurrent chemotherapy: a nationwide comparison." Poster presentation, 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Antonio, TX, 2015.
21. "Shifts in stereotactic radiosurgery platform utilization for brain metastases in the United States." Poster presentation, 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Antonio, TX, 2015.
22. "Postmastectomy radiotherapy for patients with 1-3 positive axillary lymph nodes: a patterns-of-care analysis." Poster presentation, 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Antonio, TX, 2015.
23. "Spine stereotactic radiotherapy outcomes in patients with concurrent brain metastases." Poster presentation, 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Antonio, TX, 2015.
24. "Facility case volume and outcomes for intensity-modulated radiotherapy in head and neck cancer." Poster presentation, 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Boston, MA, 2016.
25. "Impact of radiotherapy facility case volume on survival in anal cancer." Oral presentation, 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Boston, MA, 2016.
26. "Adjuvant external beam radiation therapy for surgically resected, non-metastatic anaplastic thyroid cancers." Poster presentation (as senior author and mentor to presenting author Nadia Saeed), 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Antonio, TX, 2018.
27. "Evolving national practice patterns of hypofractionated stereotactic radiation therapy versus single-fraction radiosurgery for brain metastases." Poster presentation (as senior author and mentor to presenting author Vikram Jairam), 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Antonio, TX, 2018.
28. "Emergency department visits for prescription and synthetic opioid overdoses among patients with cancer." Poster presentation (as senior author and mentor to presenting author Vikram Jairam), Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, 2019.
29. "Temporal trends in opioid prescribing patterns among oncologists in the Medicare population." Poster discussion presentation (as senior author and mentor to presenting author Vikram Jairam), Annual Meeting of the American Society of Clinical Oncology (ASCO), Virtual Meeting, 2020.
30. "Multi-facility versus single-facility concurrent chemoradiation for lung cancer." Poster presentation (as senior author and mentor to presenting author Nadia Saeed), 62nd Annual Meeting of the American Society for Radiation Oncology (ASTRO), Chicago, IL, 2021.
31. "Oligometastatic tumor size as a predictor of distant failure in synchronous oligometastatic NSCLC." Poster presentation (as senior author and mentor to presenting author Nicholas Moore), 64th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Antonio, TX, 2022.
32. "Radioresistant lung oligometastases: impact of histology and dose on local control." Poster presentation (as senior author and mentor to presenting author Nipun Verma), 64th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Antonio, TX, 2022.
33. "Trends in new and persistent opioid use in older adults with cancer." Poster presentation, Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, 2023.
34. "Opioid use, gabapentinoid use, and pain-related emergency department visits for patients living with advanced cancer." Poster presentation (as senior author and mentor to presenting author Vikram Jairam), Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, 2023.

35. "Trends in new and persistent opioid use in older adults with cancer." Poster presentation (as senior author and collaborator with presenting author Catherine Lerro), International Conference in Pharmacoepidemiology, Halifax, Nova Scotia, 2023.
36. "Comparison of pathologic outcomes following neoadjuvant regimens in resectable locally advanced non-small cell lung cancer." Poster presentation (as senior author and mentor to presenting author Nicholas Wells), World Conference on Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC), Singapore, 2023.
37. "Interim analysis of DD3: A phase IB/II trial of dose-deescalated 3-fraction SBRT for centrally located lung cancer." Poster presentation (as senior author and mentor to presenting author Gabrielle Peters), 65th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Diego, CA, 2023.
38. "Dose-escalated versus conventional hypofractionated radiotherapy for lung cancer patients in predominantly central locations." Poster presentation (as senior author and mentor to presenting author Alexander Sasse), 65th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Diego, CA, 2023.
39. "Impact of head and neck cancer treatment on CD4 T cell decline and recovery in people with HIV." Poster presentation (as senior author and mentor to presenting author Daniel Hicks), 65th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Diego, CA, 2023.
40. "Differential impact of consolidative thoracic radiotherapy in extensive-stage small cell lung cancer based on systemic therapy type and sex." Poster presentation (as senior author and mentor to presenting author Vikram Jairam), 65th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Diego, CA, 2023.
41. "Survival outcomes for oligometastatic vs. polymetastatic extensive-stage small cell lung cancer following consolidative thoracic radiotherapy." Poster presentation (as senior author and mentor to presenting author Nipun Verma), 65th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Diego, CA, 2023.
42. "Dose-volume predictors of radiation pneumonitis following thoracic hypofractionated radiotherapy." Oral presentation (as senior author and mentor to presenting author Alexander Sasse), Multidisciplinary Thoracic Cancers Symposium (MTCS), New Orleans, LA, 2023.
43. "Dosimetric factors associated with esophagitis following hypofractionated radiotherapy to the thorax." Oral presentation (as senior author and mentor to presenting author Alexander Sasse), Multidisciplinary Thoracic Cancers Symposium (MTCS), New Orleans, LA, 2023.
44. "American Radium Society Appropriate Use Criteria: Radiation therapy in the multidisciplinary management of medically inoperable stage I non-small cell lung cancer in a central/ultra-central location." Oral presentation, 106th Annual Meeting of the American Radium Society (ARS). Palm Springs, CA, 2024.
45. "Opioid prescribing trends and pain scores among adult patients with cancer in a large health system." Poster presentation (as senior author and mentor to presenting author Laura Baum), Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, 2024.
46. "Real-world practice patterns of immunotherapy, chemotherapy, and targeted therapy with radiation therapy in early-stage node-negative non-small cell lung cancer." Oral presentation (as senior author and mentor to presenting author Patrick Oh), National Cancer Institute Translational Research Program, Annual Lung Cancer SPORE Workshop, New Haven, CT, 2024.
47. "Impact of synthetic PET evaluation prior to PET-guided functional modeling in optimizing patient selection for biology-guided radiotherapy." Oral presentation (as senior author and mentor to presenting author Daniel Hicks), 66th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Washington, DC, 2024.
48. "Complete versus incomplete consolidative radiotherapy in patients with extensive-stage small cell lung cancer." Poster presentation (as senior author and mentor to presenting author James Ninia), 66th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Washington, DC, 2024.
49. "Real-world practice patterns of immunotherapy, chemotherapy, and targeted therapy with radiation therapy in early-stage node-negative non-small cell lung cancer." Poster presentation (as senior author

and mentor to presenting author Patrick Oh), 66th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Washington, DC, 2024.

50. “Workflow description of the first-in-human multi-target multimodality radiotherapy treatment utilizing biology-guided radiotherapy.” Poster presentation (as first author and collaborator with presenting author Dorine de Jong), 107th Annual Meeting of the American Radium Society (ARS), Seattle, WA, 2025.
51. “Sequencing of stereotactic body radiation therapy and chemotherapy in stage I small cell lung cancer: practice patterns and outcomes.” Poster presentation, World Conference on Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, 2025.
52. “Differential effect of neoadjuvant therapy in locally advanced non-small cell lung cancer based on sex.” Poster presentation (as senior author and mentor to presenting author Alisa Rybkin), World Conference on Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, 2025.
53. “First-in-human dual modality radiotherapy treatment in a single plan using biology-guided radiotherapy: a case report.” Oral presentation, 67th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Francisco, CA, 2025.
54. “Genomic predictors of brain metastases in non-small cell lung cancer: implications for early detection and targeted surveillance.” Poster presentation (as senior author and mentor to presenting author Victor Lee), 67th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Francisco, CA, 2025.
55. “KASTRO/KOSRO Joint Session: Radiation therapy for nonmalignant disease: transcontinental perspectives on newer indications from Korea and the United States.” Educational session organizer, 67th Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Francisco, CA, 2025.
56. “EGFR mutation subtype and risk of brain metastases from non-small cell lung cancer in the Osimertinib era.” Oral presentation (as senior author and mentor to presenting author Ameya Patel), 108th Annual Meeting of the American Radium Society (ARS), Newport Beach, CA, 2026.

Professional Service:

Peer Review Groups/Grant Study Sections:

- | | |
|------|---|
| 2019 | Ad Hoc Peer Reviewer, Grant Review Committee for “Improving Diversity & Inclusion in Radiation Oncology” Request for Proposals, Radiation Oncology Institute (ROI) |
| 2023 | Subject Matter Expert and Ad Hoc Peer Reviewer for Head and Neck Cancer, Congressionally Directed Medical Research Program’s (CDMRP) Peer Reviewed Cancer Research Program (PRCRP), United States Department of Defense (DOD) |
| 2024 | Ad Hoc Peer Reviewer, Association of Residents in Radiation Oncology Diversity, Equity, and Inclusion Publication Award, Radiation Oncology Institute (ROI) |
| 2024 | Ad Hoc Peer Reviewer, Leslie H. Warner Postdoctoral Fellowship for Cancer Research, Yale Cancer Center |
| 2024 | Ad Hoc Peer Reviewer, Catchment Area Research Award Competition, Yale Cancer Center’s Center for Community Engagement and Health Equity (CEHE) |
| 2024 | Subject Matter Expert and Ad Hoc Peer Reviewer for Lung Cancer, Congressionally Directed Medical Research Program’s (CDMRP) Peer Reviewed Cancer Research Program (PRCRP), United States Department of Defense (DOD) |
| 2024 | Expert Panel Member, American Society for Radiation Oncology (ASTRO)-AstraZeneca New Combination Therapy Scientific Challenge for Limited-Stage Small Cell Lung Cancer |
| 2025 | Ad Hoc Evaluator, Cancer Prevention Steering Committee (CPSC), National Cancer Institute (NCI) |
| 2026 | Reviewer, Medical Student Fellowship Award, American Society for Radiation Oncology (ASTRO) |
| 2026 | Scientist Reviewer, Broad Pragmatic Studies H (BPS H) Panel, Patient-Centered Outcomes Research Institute (PCORI) |

2026 Reviewer, American Society for Radiation Oncology (ASTRO)-Breast Cancer Research Foundation (BCRF) Radiation Oncology Visiting Away Rotations, Speed of Light – The ASTRO Foundation

Advisory Boards:

2021-present Advisory Board Member, AstraZeneca
 2021-present Advisory Board Member, Galera Therapeutics, Inc.
 2022-present Member, Academic Collaborative Team for Radiation Oncology Research (ACT-RAD), Flatiron Health
 2023-present Member, Publications Committee, RefleXion Medical
 2024-present Advisory Board Member, Regeneron Pharmaceuticals, Inc.
 2024-present Member, Flatiron-Yale Joint Steering Committee, Flatiron Health

Journals:

Editorial Boards

2016-present Editorial Board Member, *J Thorac Dis*
 2020-2025 Editorial Board Member, *Cancers*
 2021-2025 Associate Editor, *Front Oncol*
 2024-present Associate Editor, *Am J Clin Oncol*
 2025-present Associate Editor, *Adv Radiat Oncol*
 2026-present Editorial Board Member, *Clin Lung Cancer*
 2026-present Editorial Board Member, *Transl Lung Cancer Res*

Reviewer

2012-present Ad Hoc Peer Reviewer, *Ann Thorac Surg*
 2013-present Ad Hoc Peer Reviewer, *Cancer Causes Control*
 2014-present Ad Hoc Peer Reviewer, *Int J Radiat Oncol Biol Phys*
 2015-present Ad Hoc Peer Reviewer, *Ann Epidemiol*
 2015-present Ad Hoc Peer Reviewer, *Pract Radiat Oncol*
 2017-present Ad Hoc Peer Reviewer, *Adv Radiat Oncol*
 2017-present Ad Hoc Peer Reviewer, *Cancer*
 2017-present Ad Hoc Peer Reviewer, *Cancer Epidemiol*
 2018-present Ad Hoc Peer Reviewer, *Acta Oncol*
 2018-present Ad Hoc Peer Reviewer, *Cancer Med*
 2018-present Ad Hoc Peer Reviewer, *Eur J Cancer*
 2018-present Ad Hoc Peer Reviewer, *Head Neck*
 2018-present Ad Hoc Peer Reviewer, *JAMA Oncol*
 2018-present Ad Hoc Peer Reviewer, *J Natl Compr Canc Netw*
 2018-present Ad Hoc Peer Reviewer, *PLoS One*
 2019-present Ad Hoc Peer Reviewer, *Am J Clin Oncol*
 2019-present Ad Hoc Peer Reviewer, *Front Oncol*
 2019-present Ad Hoc Peer Reviewer, *J Am Acad Dermatol*
 2019-present Ad Hoc Peer Reviewer, *J Natl Cancer Inst*
 2019-present Ad Hoc Peer Reviewer, *Nat Commun*
 2019-present Ad Hoc Peer Reviewer, *Radiother Oncol*
 2020-present Ad Hoc Peer Reviewer, *J Clin Oncol*
 2020-present Ad Hoc Peer Reviewer, *J Neurooncol*
 2020-present Ad Hoc Peer Reviewer, *J Thorac Dis*
 2020-present Ad Hoc Peer Reviewer, *Lung Cancer*
 2020-present Ad Hoc Peer Reviewer, *Oral Oncol*
 2020-present Ad Hoc Peer Reviewer, *Sci Rep*
 2021-present Ad Hoc Peer Reviewer, *Clin Lung Cancer*
 2021-present Ad Hoc Peer Reviewer, *Int J Cancer*
 2021-present Ad Hoc Peer Reviewer, *JCO Clin Cancer Inform*

2021-present	Ad Hoc Peer Reviewer, <i>JNCI Cancer Spectr</i>
2021-present	Ad Hoc Peer Reviewer, <i>N Engl J Med</i>
2022-present	Ad Hoc Peer Reviewer, <i>Cancer Lett</i>
2023-present	Ad Hoc Peer Reviewer, <i>Clin Cancer Res</i>
2023-present	Ad Hoc Peer Reviewer, <i>JAMA Otolaryngol Head Neck Surg</i>
2023-present	Ad Hoc Peer Reviewer, <i>JAMA Netw Open</i>
2023-present	Ad Hoc Peer Reviewer, <i>J Immunother Cancer</i>
2024-present	Ad Hoc Peer Reviewer, <i>Br J Cancer</i>
2025-present	Ad Hoc Peer Reviewer, <i>CHEST</i>
2025-present	Ad Hoc Peer Reviewer, <i>Transl Lung Cancer Res</i>
2025-present	Ad Hoc Peer Reviewer, <i>JACC CardioOncol</i>
2025-present	Ad Hoc Peer Reviewer, <i>J Clin Invest</i>
2026-present	Ad Hoc Peer Reviewer, <i>Crit Rev Oncol Hematol</i>

Professional Organizations:

American Board of Radiology (ABR)

2020-present	Computer-Based Qualifying Exam Item Writer, Thoracic Cancers and Sarcomas Category Committee
2023-present	Oral Certifying Examiner, Thoracic Cancers and Sarcomas Category Committee

American Radium Society (ARS)

2021-present	Member, Appropriateness Use Criteria Thoracic Committee
2025-present	Member, Scientific Program Committee

American Society of Clinical Oncology (ASCO)

2023	Subject Matter Expert, ASCO Advantage Program: Non-Small Cell Lung Cancer
------	---

American Society for Radiation Oncology (ASTRO)

2017-2022	Member, Committee on Health Equity, Diversity, and Inclusion
2018-present	Member, Education Committee
2019-present	Member, Annual Meeting Abstract Review Committee, Health Services Research Track
2021-present	Member, Annual Meeting Abstract Review Committee, Head & Neck Track
2022	Poster Walk Leader, Annual Meeting, Head & Neck Track
2022-present	Member, Annual Meeting Abstract Review Committee, Lung Cancer / Thoracic Malignancies Track
2022-present	Member, Health Equity Education Committee

ECOG-ACRIN Cancer Research Group

2021-2024	Member, Head and Neck Core Committee
-----------	--------------------------------------

Korean American Society for Radiation Oncology (KASTRO)

2023-2025	Chair, Scientific Committee
2025-present	Vice President

National Cancer Institute (NCI)

2021-2025	Member, Previously Untreated Locally Advanced (PULA) Task Force, Head and Neck Steering Committee (HNSC)
-----------	--

National Comprehensive Cancer Network (NCCN)

2021-2025	Member, NCCN Guidelines Panel, Kaposi Sarcoma and Cancer in People Living with HIV
-----------	--

NRG Oncology

2022-present	Member, Head and Neck Cancer General Committee
2023-2025	Member, Health Care Access Working Group, Head and Neck Cancer Committee

SWOG Cancer Research Network

2019-present Member, Radiation Oncology Committee
2020-present Member, Lung Committee
2021-present Lung Committee Liaison, Radiation Oncology Committee

Yale University/Hospital System:

University Committees

2010-present Admissions Committee Interviewer, Yale College
2017-present Morse College Fellow, Yale College
2017-present Morse College First-Year Advisor, Yale College

Medical School Committees

2008-2012 Class Co-President, Yale School of Medicine
2010-2011 Member and Interviewer, Admissions Committee, Yale School of Medicine
2013-2023 Member and Interviewer, Admissions Committee, Yale School of Medicine
2016-present Reunion Program and Gift Co-Chair, Yale School of Medicine
2018-2020 Screening Sub-Committee Member, Admissions Committee, Yale School of Medicine
2021-2023 Electives Director Representative, Educational Policy and Curriculum Committee, Yale School of Medicine
2022-2023 Member, Liaison Committee on Medical Education (LCME) Education Subcommittee, Yale School of Medicine
2023-2024 Member, Advisory House Naming Committee, Yale School of Medicine
2025-present Member, Board of Permanent Officers (BPO), Yale School of Medicine
2026-present Member, Term Appointments & Promotions Committee for Academic Clinician Reviews (ACTAP), Yale School of Medicine

Departmental Committees

2018-present Member, Program Evaluation Committee, Department of Therapeutic Radiology, Yale School of Medicine
2018-2022 Chair, Clinical Competency Committee, Department of Therapeutic Radiology, Yale School of Medicine
2022-present Member, Clinical Competency Committee, Department of Therapeutic Radiology, Yale School of Medicine
2022-present Member, Appointments and Promotions Committee, Department of Therapeutic Radiology, Yale School of Medicine
2025-present Member, Radiation Oncology Faculty Physician and Physician-Scientist Search Committee, Department of Therapeutic Radiology, Yale School of Medicine
2025-present Member, Medical Oncology Faculty Physician Search Committee, Department of Medicine, Yale School of Medicine

Hospital Committees

2014-2015 Member, Graduate Medical Education Committee, Yale New Haven Hospital
2017 Member, Graduate Medical Education Grievances Panel, Yale New Haven Hospital
2017-2018 Member, Oncology Committee, Lawrence and Memorial Hospital and Westerly Hospital, Yale New Haven Hospital
2017-2018 Member, Ambulatory Clinic Committee, Smilow Cancer Hospital, Yale New Haven Hospital
2017-2021 Member, Cancer Program Committee, Smilow Cancer Hospital, Yale New Haven Hospital
2021-2024 Community Outreach and Engagement Liaison, Radiobiology and Genome Integrity Program, Yale Cancer Center
2024-present Member, Executive Cabinet, Center for Thoracic Cancers, Smilow Cancer Hospital

2024-present Member, National Clinical Trials Network Lead Academic Partnership Site Committee,
Yale Cancer Center

Public Service / Media Presence:

Public Service:

2014-2017 Staff Attending Physician, Palliative Care, The Connecticut Hospice, Inc., Branford, CT
2016-2020 Ad Hoc Editor, Central Nervous System Editor, Head and Neck Editor, Rad Onc
Questions, LLC
2017 Panelist, “Lung Cancer Living Room.” Bonnie J. Addario Lung Cancer Foundation, New
Haven, CT
2020, 2022 Commentary Writer, PracticeUpdate
2021 Panelist, “Lung Cancer.” Yale’s Review of Advances in Oncology: Highlights from the
ASCO Annual Meeting, Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT
2021 Panelist, “Smilow Shares: Lung Cancer Awareness Month – New Treatment Advances and
Innovations” Webinar
2022 Panelist, “Lung Cancer.” Yale’s Review of Advances in Oncology: Highlights from the
ASCO Annual Meeting, Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT
2023 Speaker and Panelist, “State of the Science Summit: Lung Cancer” presented by OncLive,
Trumbull, CT
2023 Speaker and Panelist, “Updates on Lung Cancer Diagnosis through Treatment.” Milford,
CT
2023 Panelist, “Lung Cancer.” Yale’s Review of Advances in Oncology: Highlights from the
ASCO Annual Meeting, Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT
2023 Panelist, “Learning about Lung Cancer: a Community Event in Recognition of Lung
Cancer Awareness Month.” New Haven, CT
2024 Speaker, “New Tools in the Toolbox: Surgical and Radiotherapy Advances at Yale.” Yale’s
Review of Advances in Oncology: Highlights from the ASCO Annual Meeting, Yale
Cancer Center and Smilow Cancer Hospital, New Haven, CT
2024 Panelist, “Lung Cancer.” Yale’s Review of Advances in Oncology: Highlights from the
ASCO Annual Meeting, Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT
2024 Panelist, “Screening of ‘The Last Ecstatic Days’ Documentary.” Yale School of the
Environment, New Haven, CT
2024 Panelist, “Engagement in Cooperative Groups.” Yale Cancer Center National Clinical
Trials Network (NCTN) Summit, New Haven, CT
2024 Panelist, “Lung Cancer Awareness Patient and Community Event.” Yale Cancer Center and
Smilow Cancer Hospital, New Haven, CT
2025 Podcast Guest, “Dr. Henry Park: Advanced Radiation Therapy Guided by PET Imaging.”
Outperform Cancer, Charlotte, VT
2025 Featured Violin Performer, Opening Plenary Session, World Conference on Lung Cancer,
Barcelona, Spain
2025 Course Co-Director, Yale’s Review of Advances in Oncology: Highlights from the ASCO
Annual Meeting, Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT
2026 Panelist, “Best Practices in NCTN Clinical Research.” National Clinical Trials Network
Summit, Yale Cancer Center, New Haven, CT.

Media Presence:

2016 Quoted Expert, Yale Daily News. “Case volume correlates with survival rate, Yale
researchers find.”
<https://yaledailynews.com/blog/2016/10/11/case-volume-correlates-with-survival-rate-yale-researchers-find/>
2017 Quoted Expert, Medscape. “‘Alternative medicine’ for cancer ups death risk.”
<https://www.medscape.com/viewarticle/884117>

- 2018 Invited Guest, “Yale Cancer Center Answers” Radio Show on WNPR on “Radiation treatment and side effects.”
<https://medicine.yale.edu/media-player/cancer-answers-radiation-treatment-and-side-effects-october-14-2018/>
- 2020 Quoted Expert, HemOnc Today. “Opioid use among cancer survivors: Striking a balance.”
<https://www.healio.com/news/hematology-oncology/20200924/opioid-use-among-cancer-survivors-striking-a-balance>
- 2021 Invited Guest, “Yale Cancer Center Answers” Radio Show on WNPR on “Radiotherapy for lung cancer.”
<https://www.yalemedicine.org/podcasts/radiotherapy-for-lung-cancer>
- 2021 Writer, Healthline. “Ask the Expert: What’s the future of EGFR-positive NSCLC treatment?”
<https://www.healthline.com/health/nsclc/future-of-egfr-positive-nsclc-treatment>
- 2021 Featured Expert, USA Today. “Fact check: False claim that cancer is trying to heal a person, not kill them.”
<https://www.usatoday.com/story/news/factcheck/2021/10/21/fact-check-cancer-does-not-remove-toxins-body/8458999002/>
- 2022 Cited Article, Philadelphia Inquirer. “Penn Medicine/Virtua Health to open South Jersey’s first proton therapy center for cancer patients.”
<https://www.inquirer.com/health/virtua-voorhees-penn-medicine-proton-therapy-cancer-20221013.html>
- 2022 Quoted Expert, Cancer Therapy Advisor. “Opioids and cancer: How to prevent and manage misuse.”
<https://www.cancertherapyadvisor.com/home/cancer-topics/general-oncology/cancer-opioids-misuse-how-to-prevent-manage/>
- 2023 Quoted Expert, Yale Daily News. “YNHH’s Smilow Cancer Hospital pioneers new radiotherapy technology”
<https://yaledailynews.com/blog/2023/03/09/ynhhs-smilow-cancer-hospital-pioneers-new-radiotherapy-technology/>
- 2023 Cited Article, CNN. “Young children are increasingly victims of opioid epidemic, study finds.” <https://www.cnn.com/2023/03/08/health/infant-opioid-deaths/index.html>
- 2023 Speaker, OncLive TV. “Dr. Park on determining treatment approaches in NSCLC.”
<https://www.onclive.com/view/dr-park-on-determining-treatment-approaches-in-nsclc>
- 2023 Speaker, OncLive TV. “Dr. Park on the role of radiation therapy in NSCLC.”
<https://www.onclive.com/view/dr-park-on-the-role-of-radiation-therapy-in-nsclc>
- 2023 Speaker, VuMedi. “Consolidation IO following CRT in stage III NSCLC.”
<https://www.vumedi.com/video/consolidation-io-following-crt-in-stage-iii-nsclc/>
- 2023 Speaker, Oncology Data Advisor. “Additional advances in small cell lung cancer radiotherapy with Henry Park.”
<https://oncdata.com/news/additional-advances-in-small-cell-lung-cancer-radiotherapy-with-henry-park-md-mph-1>
- 2023 Featured Expert, Yale School of Medicine. “Henry S. Park, MD, MPH, in honor of Lung Cancer Awareness Month.”
<https://medicine.yale.edu/news-article/henry-s-park-md-mph-in-honor-of-lung-cancer-awareness-month/>
- 2024 Quoted Expert, MedPage Today. “Hypofractionated chemoradiation with adaptive SABR appeared effective in NSCLC.”
<https://www.medpagetoday.com/radiology/therapeuticradiology/108237>
- 2024 Quoted Expert, Yale School of Medicine. “New YSM colleges enhance community and mentorship.”
<https://medicine.yale.edu/news-article/new-ysm-colleges-enhance-community-and-mentorship/>
- 2024 Featured Expert, Journal of Thoracic Disease. “Meeting the editorial board member of JTD: Dr. Henry S. Park.”

- <https://jtd.amegroups.org/post/view/meeting-the-editorial-board-member-of-jtd-dr-henry-s-park>
- 2024 Featured Expert, Business Wire. “RefleXion announces world’s first single-plan multi-modality radiotherapy to patient with stage 4 cancer at Yale New Haven Health.”
<https://www.businesswire.com/news/home/20240905760952/en/RefleXion-Announces-World%E2%80%99s-First-Single-Plan-Multi-Modality-Radiotherapy-to-Patient-with-Stage-4-Cancer-at-Yale-New-Haven-Health>
- 2024 Featured Expert, Yahoo! Finance. “RefleXion announces first ever combination radiotherapy using X1 system.”
<https://finance.yahoo.com/news/reflexion-announces-first-ever-combination-115307142.html>
- 2025 Quoted Expert, Popsugar. “Beware of the Cancer Scammers.”
<https://www.popsugar.com/health/cancer-scammers-49435607>
- 2025 Quoted Expert, Popsugar. “How Smilow doctors are saving my life: a cancer survivor’s Story.”
<https://www.yalemedicine.org/news/how-smilow-doctors-are-saving-my-life>
- 2026 Invited Guest, “Yale Cancer Center Answers” Radio Show on WNPR on “What to know about natural cancer ‘cures.’”
<https://medicine.yale.edu/cancer/media-player/yca-park-published-radio-audio/>

Bibliography:

Peer-Reviewed Original Research

1. **Park HS**, Roman SA, Sosa JA. Outcomes from 3,144 adrenalectomies in the U.S.: which matters more, surgeon volume or specialty? *Arch Surg* 2009 Nov; 144(11):1060-1067.
2. **Park HS**, Roman SA, Sosa JA. Treatment patterns of aging Americans with differentiated thyroid cancer. *Cancer* 2010 Jan; 116(1):20-30.
3. **Park HS**, Detterbeck FC, Boffa DJ, Kim AW. Impact of hospital volume of thoracoscopic lobectomy on primary lung cancer outcomes. *Ann Thorac Surg* 2012 Feb; 93(2):372-379.
4. Rauch PJ, **Park HS**, Knisely JP, Chiang VL, Vortmeyer AO. Delayed radiation-induced vasculitic leukoencephalopathy. *Int J Radiat Oncol Biol Phys* 2012 May; 83(1):369-375.
5. **Park HS**, Gross CP, Makarov DV, Yu JB. Immortal time bias: a frequently unrecognized threat to validity in the evaluation of adjuvant radiation therapy. *Int J Radiat Oncol Biol Phys* 2012 Aug; 83(5):1365-1373.
6. Buscariollo DL, **Park HS**, Roberts KB, Yu JB. Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. *Cancer* 2012 Sep; 118(17):4212-4219.
7. **Park HS***, Schoenfeld JD*, Mailhot RB, Shive ML, Hartman RI, Ogembo RK, Mucci LA. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. *Ann Oncol* 2013 Jun; 24(6):1427-1434. *co-first authorship
8. Law TD, Boffa DJ, Detterbeck FC, Wang Z, **Park HS**, Kim AW. Lethality of cardiovascular events highlights the variable impact of complication type between thoracoscopic and open pulmonary lobectomies. *Ann Thorac Surg* 2014 Mar; 97(3):993-999.
9. Rutter CE, Corso CD, **Park HS**, Yeboa DN, Mancini BR, Lester-Coll NH, Kim AW, Decker RH. Increase in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States. *Lung Cancer* 2014 Sep; 85(3):390-394.
10. Rutter CE, Yu JB, Wilson LD, **Park HS**. Assessment of national practice for palliative radiotherapy for bone metastases suggests marked underutilization of single-fraction regimens in the United States. *Int J Radiat Oncol Biol Phys* 2015 Mar; 91(3):548-555.
11. Ogembo RK, Gona PN, Seymour AJ, **Park HS**, Bain PA, Maranda L, Ogembo JG. Prevalence of human papillomavirus genotype among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis. *PLoS One* 2015 Apr; 10(4):e0122488.

12. **Park HS**, Harder EM, Mancini BR, Decker RH. Central vs. peripheral tumor location: influence on survival, local control, and toxicity following stereotactic body radiotherapy for primary non-small cell lung cancer. *J Thorac Oncol* 2015 May; 10(5):832-837.
13. Wang EH, Rutter CE, Corso CD, Decker RH, Wilson LD, Kim AW, Yu JB, **Park HS**. Patients selected for definitive concurrent chemoradiation at high-volume facilities achieve improved survival in stage III non-small cell lung cancer. *J Thorac Oncol* 2015 Jun; 10(6):937-943.
14. Rutter CE, **Park HS**, Killelea BK, Evans SB. Growing use of mastectomy for ductal carcinoma in situ of the breast among young women in the United States. *Ann Surg Oncol* 2015 Jul; 22(7):2378-2386.
15. **Park HS**, Decker RH, Wilson LD, Yu JB. Prophylactic cranial irradiation for patients with locally advanced non-small cell lung cancer at high risk for brain metastases. *Clin Lung Cancer* 2015 Jul; 16(4):292-297.
16. Rutter CE, Lester-Coll NH, Mancini BR, Corso CD, **Park HS**, Yeboa DN, Gross CP, Evans SB. The evolving role of adjuvant radiotherapy in elderly women with early stage breast cancer. *Cancer* 2015 Jul; 121(14):2331-2340.
17. **Park HS**, Ratner ES, Lucarelli L, Polizzi S, Higgins SA, Damast S. Predictors of vaginal stenosis following intravaginal high-dose-rate brachytherapy for endometrial carcinoma. *Brachytherapy* 2015 Jul-Aug; 14(4):464-470.
18. Corso CD, **Park HS**, Kim AW, Yu JB, Husain ZA, Decker RH. Racial disparities in the use of SBRT for treating early-stage NSCLC. *Lung Cancer* 2015 Aug; 89(2):133-138.
19. Wang EH, Corso CD, Rutter CE, **Park HS**, Chen AB, Kim AW, Wilson LD, Decker RH, Yu JB. Postoperative radiation therapy is associated with improved overall survival in incompletely resected stage II and III non-small cell lung cancer. *J Clin Oncol* 2015 Sep; 33(25):2727-2734.
20. Rutter CE, **Park HS**, Corso CD, Yeboa DN, Mancini BR, Lester-Coll NH, Kim AW, Decker RH. Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation. *Lung Cancer* 2015 Nov; 90(2):243-248.
21. Harder EM, **Park HS**, Nath SK, Mancini BR, Decker RH. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy. *Pract Radiat Oncol* 2015 Nov-Dec; 5(6):e643-649.
22. Rutter CE, **Park HS**, Corso CD, Lester-Coll NH, Mancini BR, Yeboa DN, Johung KL. The addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: an analysis of the National Cancer Data Base. *Cancer* 2015 Dec; 121(23):4141-4149.
23. Corso CD, Rutter CE, **Park HS**, Lester-Coll NH, Kim AW, Wilson LD, Husain ZA, Lilenbaum RC, Yu JB, Decker RH. Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer. *J Clin Oncol* 2015 Dec; 33(36):4240-4246.
24. **Park HS**, Wang EH, Rutter CE, Corso CD, Chiang VL, Yu JB. Changing patterns of Gamma Knife versus linear accelerator-based stereotactic radiosurgery for brain metastases in the US. *J Neurosurg* 2016 Apr; 124(4):1018-1024.
25. Lester-Coll NH, **Park HS**, Rutter CE, Corso CD, Young MR, Ratner ES, Litkouhi B, Decker RH, Yu JB, Damast S. Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base. *Gynecol Oncol* 2016 Jul; 142(1):54-61.
26. Mancini BR, **Park HS**, Harder EM, Rutter CE, Corso CD, Decker RH, Husain ZA. Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients. *Lung Cancer* 2016 Jul; 97:22-27.
27. Subramanian HE, **Park HS**, Barbieri A, Mahajan A, Judson BL, Mehra S, Yarbrough WG, Burtress BA, Husain ZA. Pretreatment predictors of adjuvant chemoradiation in patients receiving transoral robotic surgery for squamous cell carcinoma of the oropharynx: a case control study. *Cancers Head Neck* 2016 Jul; 1(7):1-8.
28. Colaco RJ*, **Park HS***, Laurans MS, Chiang VL, Yu JB, Husain ZA. Spine stereotactic radiotherapy outcomes in patients with concurrent brain metastases. *Cureus* 2016 Jul; 8(7):e679. *co-first authorship

29. Stahl JM, **Park HS**, Silasi DA, Azodi M, Damast S. Influence of robotic hysterectomy approach on vaginal cuff healing and brachytherapy initiation in endometrial carcinoma patients. *Pract Radiat Oncol* 2016 Jul-Aug; 6(4):226-232.
30. Kole AJ*, **Park HS***, Yeboa DN, Rutter CE, Corso CD, Aneja S, Lester-Coll NH, Mancini BR, Knisely JP, Yu JB. Concurrent chemoradiotherapy versus radiotherapy alone for “biopsy-only” glioblastoma multiforme. *Cancer* 2016 Aug; 122(15):2364-2370. *co-first authorship
31. Lester-Coll NH, **Park HS**, Rutter CE, Corso CD, Mancini BR, Yeboa DN, Kim SP, Gross CP, Yu JB. The association between evaluation at academic centers and the likelihood of expectant management in low-risk prostate cancer. *Urology* 2016 Oct; 96:128-135.
32. Harder EM, **Park HS**, Chen Z, Decker RH. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy. *Pract Radiat Oncol* 2016 Nov-Dec; 6(6):e353-359.
33. Kann BH, **Park HS**, Lester-Coll NH, Yeboa DN, Benitez V, Khan AJ, Bindra RS, Marks AM, Roberts KB. Postoperative radiotherapy patterns of care and survival implications for medulloblastoma in young children. *JAMA Oncol* 2016 Dec; 2(12):1574-1581.
34. Stahl JM, Corso CD, Verma V, **Park HS**, Nath SK, Husain ZA, Simone CB II, Kim AW, Decker RH. Trends in stereotactic body radiation therapy for stage I small cell lung cancer. *Lung Cancer* 2017 Jan; 103:11-16.
35. Stahl JM, Corso CD, **Park HS**, An Y, Rutter CE, Han D, Roberts KB. The effect of microscopic margin status on survival in adult retroperitoneal soft tissue sarcomas. *Eur J Surg Oncol* 2017 Jan; 43(1):168-174.
36. Wang EH, **Park HS**, Rutter CE, Gross CP, Soulos PR, Yu JB, Evans SE. Association between access to accelerated partial breast irradiation access and utilization of adjuvant radiation therapy. *Cancer* 2017 Feb; 123(3):502-511.
37. Kann BH, Lester-Coll NH, **Park HS**, Yeboa DN, Kelly JR, Baehring JM, Becker KP, Yu JB, Bindra RS, Roberts KB. Adjuvant chemotherapy and overall survival in adult medulloblastoma. *Neuro Oncol* 2017 Feb; 259-269.
38. Tchouta LN, **Park HS**, Boffa DJ, Blasburg JD, Detterbeck FC, Kim AW. Hospital volume and outcomes of robot-assisted thoracoscopic lobectomies. *Chest* 2017 Feb; 151(2):329-339.
39. Husain ZA, Chen T, Corso CD, Wang Z, **Park HS**, Judson BL, Yarbrough WG, Deshpande H, Mehra S, Kuo P, Decker RH, Burtneess BA. A comparison of prognostic ability of staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma. *JAMA Oncol* 2017 Mar; 3(3):358-365.
40. Kole AJ, Stahl JM, **Park HS**, Khan SA, Johung KL. Predictors of non-adherence to NCCN guideline recommendations for the management of stage I anal canal cancer. *J Natl Compr Canc Netw* 2017 Mar; 15(3):355-362.
41. Kann BH, **Park HS**, Yeboa DN, Aneja S, Girardi M, Foss F, Roberts KB, Wilson LD. Annual facility treatment volume and patient survival for mycosis fungoides and Sézary syndrome. *Clin Lymphoma Myeloma Leuk* 2017 Aug; 17(8):520-526.
42. Gao SJ, **Park HS**, Corso CD, Rutter CE, Kim AW, Johung KL. Role of adjuvant treatment in esophageal cancer with incidental pathologic node positivity. *Ann Thorac Surg* 2017 Jul; 104(1):267-274.
43. An Y, **Park HS**, Kelly JR, Yarbrough WG, Burtneess BA, Contessa JN, Decker RH, Koshy M, Husain ZA. The prognostic value of extracapsular extension in human papilloma virus-associated oropharyngeal squamous cell carcinoma. *Cancer* 2017 Jul; 123(14):2762-2772.
44. Corso CD, **Park HS**, Moreno AC, Kim AW, Husain ZA, Yu JB, Decker RH. Stage I lung SBRT clinical practice patterns. *Am J Clin Oncol* 2017 Aug; 40(4):358-361.
45. Kelly JR, **Park HS**, An Y, Contessa JN, Yarbrough WG, Burtneess BA, Decker RH, Husain ZA. Comparison of survival outcomes among human papillomavirus-negative cT1-2 N1-2b oropharyngeal squamous cell cancer patients treated with upfront surgery versus definitive chemoradiation therapy: an observational study. *JAMA Oncol* 2017 Aug; 3(8):1107-1111.
46. Lee NC, Kelly JR, **Park HS**, Yarbrough WG, Burtneess BA, Husain ZA. The risk of level IB nodal involvement in oropharynx cancer: guidance for submandibular gland sparing irradiation. *Pract Radiat Oncol* 2017 Sept-Oct; 7(5):e317-321.

47. Bledsoe TJ, **Park HS**, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Hypofractionated radiotherapy for patients with early-stage glottic cancer: patterns of care and survival. *J Natl Cancer Inst* 2017 Oct; 109(10):1-9.
48. Harder EM, Chen Z, **Park HS**, Mancini BR, Decker RH. Dose-volume predictors of esophagitis after thoracic stereotactic body radiation therapy. *Am J Clin Oncol* 2017 Oct; 40(5):477-482.
49. Yeboa DN, Rutter CE, **Park HS**, Lester-Coll NH, Corso CD, Mancini BR, Bindra RS, Contessa JN, Yu JB. Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas. *Radiother Oncol* 2017 Nov; 125(2):258-265.
50. Lester-Coll NH, Young MR, **Park HS**, Ratner ES, Litkouhi B, Damast S. Adjuvant therapy use and survival in stage II endometrial cancer. *Int J Gynecol Cancer* 2017 Nov; 27(9):1904-1911.
51. Gao SJ, **Park HS**, Corso CD, Rutter CE, Khan S, Johung KL. Post-operative radiotherapy is associated with improved survival in esophageal cancer with positive surgical margins. *J Gastrointest Oncol* 2017 Dec; 8(6):953-961.
52. Kann BH, **Park HS**, Johnson SB, Chiang VL, Yu JB. Radiosurgery for brain metastases: practice patterns, adoption, and disparities in the United States. *J Natl Compr Canc Netw* 2017 Dec; 15(12):1494-1502.
53. Chowdhary M, Okwan-Duodu D, Switchenko JM, Press RH, Jhaveri J, Buchwald ZS, Zhong J, Chapman BV, Bindra RS, Contessa JN, **Park HS**, Yu JB, Decker RH, Olson JJ, Oyesiku NM, Abrams RA, Shu HG, Curran WJ Jr, Crocker IR, Patel KR. Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. *J Neurooncol* 2018 Jan; 136(2):289-298.
54. Johnson SB, **Park HS**, Gross CP, Yu JB. Use of alternative medicine for cancer and its impact on survival. *J Natl Cancer Inst* 2018 Jan; 110(1):121-124.
55. Wang EH, Corso CD, **Park HS**, Chen AB, Wilson LD, Kim AW, Decker RH, Yu JB. Association between radiation dose and outcomes with postoperative radiotherapy for N0-N1 non-small cell lung cancer. *Am J Clin Oncol* 2018 Feb; 41(2):152-158.
56. Cheraghlou S, Yu PK, Otremba MD, **Park HS**, Bhatia AK, Zogg CK, Mehra S, Yarbrough WG, Judson BL. Treatment deintensification in human papillomavirus-positive oropharynx cancer: outcomes from the National Cancer Database. *Cancer* 2018 Feb; 124(4):717-726.
57. Bledsoe TJ, **Park HS**, Rutter CE, Aneja S, Nguyen PL, Yu JB. Impact of health insurance status on prostate cancer treatment modality selection in the United States. *Am J Clin Oncol* 2018 Nov; 41(11):1062-1068.
58. Kelly JR, **Park HS**, An Y, Yarbrough WG, Contessa JN, Decker R, Mehra S, Judson BL, Burtness B, Husain Z. Upfront surgery versus definitive chemoradiotherapy in patients with human papillomavirus-associated oropharyngeal squamous cell cancer. *Oral Oncol* 2018 Apr; 79:64-70.
59. Breen W, Kelly J, **Park HS**, Son Y, Sasaki C, Wilson L, Decker R, Husain ZA. Permanent interstitial brachytherapy for previously irradiated head and neck cancer. *Cureus* 2018 Apr; 10(4):e2517.
60. Hong JC, Gross CP, Shafman TD, Hu X, Yu JB, Ross R, Finkelstein SE, Dosoretz AP, **Park HS**, Soulos PR, Evans SB. Radiation dose and cardiac risk in breast cancer treatment: an analysis of modern radiotherapy. *Pract Radiat Oncol* 2018 May-June; e79-e86.
61. Li H, **Park HS**, Osborn HA, Judson BL. Sex differences in patients with high risk HPV-associated and HPV-negative oropharyngeal and oral cavity squamous cell carcinomas. *Cancers Head Neck* 2018 Jun; 3:4.
62. Kann BH, Aneja S, Loganadane G, Kelly JR, Smith S, Decker RH, Yu JB, **Park HS**, Yarbrough WG, Malhotra A, Burtness BA, Husain ZA. Pretreatment identification of head and neck cancer nodal metastasis and extranodal extension using deep learning neural networks. *Sci Rep* 2018 Sep; 8(1):14036.
63. Johnson SB, **Park HS**, Gross CP, Yu JB. The relationship among complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers. *JAMA Oncol* 2018 Oct; 4(10):1375-1381.
64. Lee NC, Kelly JR, **Park HS**, An Y, Judson BL, Burtness BA, Husain ZA. Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma. *Oral Oncol* 2018 Oct; 85:35-39.

65. Zaorsky NG, Zhang Y, Tuanquin L, Bluethmann SM, **Park HS**, Chichilli VM. Suicide among cancer patients. *Nat Commun* 2019 Jan; 10(1):207.
66. Chowdhary M, Lee A, Gao S, Barry PN, Diaz R, Bagadiya NR, **Park HS**, Yu JB, Wilson LD, Moran MS, Higgins SA, Knowlton CA, Patel KR. Is proton therapy a “pro” for breast cancer? A comparison of proton vs. non-proton radiotherapy using the National Cancer Database. *Front Oncol* 2019 Jan; 8:678.
67. Leapman MS, Wang R, **Park HS**, Yu JB, Weinreb JC, Gross CP, Ma X. Association between prostate MRI and observation for low-risk prostate cancer. *Urology* 2019 Feb; 124:98-106.
68. Yu JB, Singh C, Bindra RS, Contessa JN, Husain Z, Hansen JE, **Park HS**, Roberts KB, Bond JE, Tien CJ, Guo F, Colaco RJ, Housri N, Magnuson MJ, Mahajan A, Omay SB, Chiang VL. Results of a pilot / phase II study of Gamma Knife radiosurgery for brain metastases and implications for future prospective clinical trials. *J Radiat Oncol* 2019 Mar; 8(1):39-46.
69. Kann BH, Miccio JA, Stahl JM, Ross R, Verma V, Dosoretz AP, **Park HS**, Shafman TD, Gross CP, Yu JB, Decker RH. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: a multi-institutional analysis. *Radiother Oncol* 2019 Mar; 132:188-196.
70. Stahl JM, Qian JM, Tien CJ, Carlson DJ, Chen Z, Ratner ES, **Park HS**, Damast S. Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy. *Support Cancer Care* 2019 Apr; 27(4):1425-1433.
71. Cheraghlou S, Schettino A, Zogg CK, Otremba MD, Bhatia A, **Park HS**, Osborn HA, Mehra S, Yarbrough WG, Judson BL. Adjuvant chemotherapy is associated with improved survival for late-stage salivary squamous cell carcinoma. *Laryngoscope* 2019 Apr; 129(4):883-889.
72. Kann BH, Verma V, Stahl JM, Ross R, Dosoretz AP, Shafman TD, Gross CP, **Park HS**, Yu JB, Decker RH. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma. *Radiother Oncol* 2019 May; 134:44-49.
73. Lee NC, Kelly JR, An Y, **Park HS**, Judson BL, Burtneess BA, Husain ZA. Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma. *Cancer* 2019 Jun; 125(12):2018-2026.
74. Jairam V, Kann BH, **Park HS**, Miccio JA, Beckta JM, Yu JB, Prabhu RS, Gao SJ, Mehta MP, Curran WJ, Bindra RS, Contessa JN, Patel KR. Defining an intermediate-risk group for low-grade glioma: A National Cancer Database Analysis. *Anticancer Res* 2019 Jun; 39(6):2911-2918.
75. Kole AJ, **Park HS**, Johnson S, Kelly JR, Moran MS, Patel A. Overall survival is improved when DCIS accompanies invasive breast cancer. *Nat Sci Rep* 2019 Jul; 9(1):9934.
76. Jairam V, Lee V, **Park HS**, Thomas CR, Melnick ER, Gross CP, Presley CJ, Adelson KB, Yu JB. Treatment-related complications of chemotherapy and radiotherapy: an analysis of the Nationwide Emergency Department Sample. *JAMA Oncol* 2019 Jul; 5(7):1028-1035.
77. Rahimy E, Jagsi R, **Park HS**, Moran JM, Cervino L, Albert A, Lee A, Evans SB. Quality at the American Society for Radiation Oncology (ASTRO) annual meeting: gender balance among invited speakers and associations with panel success. *Int J Radiat Oncol Biol Phys* 2019 Aug; 104(5):987-997.
78. Li H, Torabi SJ, **Park HS**, Yarbrough WG, Mehra S, Choi R, Judson BL. Clinical value of transoral robotic surgery: nationwide results from the first 5 years of adoption. *Laryngoscope* 2019 Aug; 129(8):1844-1855.
79. Loganadane G, Kann BH, **Park HS**, Johnson SB, Mehra S, Judson BL, Bhatia A, Belkacemi Y, Yarbrough WG, Burtneess B, Husain ZA. Clinical outcomes of head and neck cancer patients who undergo resection, but forgo adjuvant therapy. *Anticancer Res* 2019 Sep; 39(9):4885-4890.
80. Lee NC, Eskander A, **Park HS**, Mehra S, Burtneess BA, Husain ZA. Pathologic staging changes in oral cavity squamous cell carcinoma: stage migration and implications for adjuvant treatment. *Cancer* 2019 Sep; 125(17):2975-2983.
81. Lee A, Albert A, Griffith K, Evans SB, Rahimy E, **Park HS**, Cervino LI, Moran JM, Jagsi R. Mentorship in radiation oncology: role of gender diversity in abstract presenting and senior author dyads on subsequent high-impact publications. *Adv Radiat Oncol* 2019 Oct; 5(2):292-296.

82. Miccio JA, Verma V, Kelly JA, Kann BH, An Y, **Park HS**, Eskander A, Burtneess BA, Husain ZA. Impact of contralateral lymph nodal involvement on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition. *Oral Oncol* 2019 Dec; 99:104447.
83. Jairam V, Lincoln H, Brown D, **Park HS**, Evans SB. Error types and associations with clinically significant events leading to FDA recalls of linear accelerators and related products. *Pract Radiat Oncol* 2020 Jan-Feb; 10(1):e8-e15.
84. Pourghaderi P, Yuquimpo KM, Guetter CR, Mansfield L, **Park HS**. Outcomes following lower extremity amputation in patients with diabetes mellitus and peripheral arterial disease. *Ann Vasc Surg* 2020 Feb; 63:259-268.
85. Kann BH, Hicks DF, Payabvash S, Mahajan A, Du J, Gupta V, **Park HS**, Yu JB, Yarbrough WG, Burtneess BA, Husain ZA, Aneja S. Multi-institutional validation of deep learning for pretreatment identification of extranodal extension in head and neck squamous cell carcinoma. *J Clin Oncol* 2020 Apr; 38(12):1304-1311.
86. Saeed NA, Kelly JR, Deshpande HA, Bhatia AK, Burtneess BA, Judson BL, Mehra S, Edwards HA, Yarbrough WG, Peter PR, Holt EH, Decker RH, Husain ZA, **Park HS**. Adjuvant external beam radiotherapy for surgically resected, non-metastatic anaplastic thyroid cancer. *Head Neck* 2020 May; 42(5):1031-1044.
87. Lee V, Jairam V, Yu JB, **Park HS**. Nationwide patterns of hemorrhagic stroke among patients hospitalized with brain metastases: influence of primary cancer diagnosis and anticoagulation. *Sci Rep* 2020 Jun; 10(1):10084.
88. Peters GW, Decker RH, **Park HS**, Yu JB, Evans SB. Resident attitudes and benefits of mock oral board examinations in radiation oncology. *BMC Med Educ* 2020 Jun; 20(1):203.
89. Hsiang W, Han X, Jemal A, Nguyen KA, Shuch B, **Park HS**, Yu JB, Gross CP, Davidoff AJ, Leapman MS. The association between the Affordable Care Act and insurance status, stage, and treatment in patients with testicular cancer. *Urol Pract* 2020 Jul; 7(4):252-258.
90. Jairam V, Yang DX, Verma V, Yu JB, **Park HS**. National patterns in prescription opioid use and misuse among adult cancer survivors. *JAMA Netw Open* 2020 Aug; 3(8):e2013605.
91. Miccio JA, Barsky A, Gao S, Verma V, Noticewala SS, Jairam V, Johnson SB, Yu JB, Hansen JE, Aneja S, An Y, Decker RH, Omay SB, Li J, Kurtz GA, Alonso-Basanta M, Lee JY, Chiang VL, **Park HS**. Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy. *J Radiosurg SBRT* 2020 Aug; 7(1):19-27.
92. Jairam V, Yang DX, Yu JB, **Park HS**. Emergency department visits for opioid overdoses among patients with cancer. *J Natl Cancer Inst* 2020 Sep; 112(9):938-943.
93. Jairam V, Lee V, Yu JB, **Park HS**. Nationwide patterns of pathologic fractures among patients hospitalized with bone metastases. *Am J Clin Oncol* 2020 Oct; 43(10):720-726.
94. Yang DX, Verma V, An Y, Yu JB, Sprenkle PC, Leapman MS, **Park HS**. Radiation dose to the rectum with definitive radiotherapy and hydrogel spacer versus post-prostatectomy radiotherapy. *Adv Radiat Oncol* 2020 Nov-Dec; 5(6):1225-1231.
95. Lee V, Camp C, Jairam V, **Park HS**, Yu JB. Emergency department visits for firearm-related injuries among youth in the United States, 2006–2015. *J Law Med Ethics* 2020 Dec; 48(4 suppl):67-73.
96. Miccio JA, Talcott WJ, Patel T, **Park HS**, Cecchini M, Salem RR, Khan SA, Stein S, Kortmansky JS, Lacy J, Narang A, Herman J, Jabbour SK, Hallemeier CL, Johung K, Jethwa KR. Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A National Cancer Database analysis. *Clin Transl Radiat Oncol* 2020 Dec; 27:15-23.
97. He Y, Li X, Dang S, Liu G, Liu X, Chen S, Zhang X, Hofman P, Uchino J, **Park HS**, Pacheco JM, Tabbo F, Xu M, Song L, Zhou C, on behalf of the AME Lung Cancer Collaborative Group. Mutational profile predicts response and survival to first-line chemotherapy in lung cancer. *Adv Sci* 2020 Dec; 8(4):2003263.
98. Lee NCJ, Eskander A, Miccio JA, **Park HS**, Shah C, Rutenberg M, Hosni A, Husain ZA. Evaluation of head and neck soft tissue sarcoma 8th edition pathologic staging system and proposal of a novel stage grouping system. *Oral Oncol* 2021 Mar; 114:105137.

99. Pathak R, Lopes G, Yu H, Aryal MR, Ji W, Frumento KS, Wallis CJ, Klaassen Z, **Park HS***, Goldberg SB*. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: a network meta-analysis of randomized trials. *Cancer* 2021 Mar; 127(5):709-719. *co-senior authorship.
100. Jairam V, Yang DX, Pasha S, Soulos PR, Gross CP, Yu JB, **Park HS**. Temporal trends in opioid prescribing patterns among oncologists in the Medicare population. *J Natl Cancer Inst* 2021 Mar; 113(3):274-281.
101. Yang DX, Khera R, Miccio JA, Jairam V, Chang E, Yu JB, **Park HS**, Krumholz HM, Aneja S. Missing data in the medical record for oncology patients: prevalence and association with outcomes. *JAMA Netw Open* 2021 Mar; 4(3):e211793.
102. Ghabili K, **Park HS**, Yu JB, Sprenkle PC, Kim SP, Nguyen KA, Ma X, Gross CP, Leapman MS. National trends in the management of patients with positive surgical margins at radical prostatectomy. *World J Urol* 2021 Apr; 39(4):1141-1151.
103. Diamond BH, Jairam V, Zuberi S, Li JY, Marquis TJ, Rutter CE, **Park HS**. Linear accelerator-based single-fraction stereotactic radiosurgery versus hypofractionated stereotactic radiotherapy for intact and resected brain metastases under 3 cm: a multi-institutional retrospective analysis. *J Radiosurg SBRT* 2021 May; 7(3):179-187.
104. Jacobs D, Olino K, **Park HS**, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary treatment selection for clinically node-negative Merkel cell carcinoma of the head and neck. *Otolaryngol Head Neck Surg* 2021 Jun; 164(6):1214-1221.
105. Jacobs D, Torabi SJ, **Park HS**, Rahmati R, Young MR, Mehra S, Judson BL. Revisiting the Radiation Therapy Oncology Group 1221 hypothesis: treatment for stage III/IV HPV-negative oropharyngeal cancer. *Otolaryngol Head Neck Surg* 2021 Jun; 164(6):1240-1248.
106. Miccio JA, Talcott WJ, Jairam V, **Park HS**, Yu JB, Leapman MS, King MT, Nguyen PL, Kann BH. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. *Prostate Cancer Prostatic Dis* 2021 Jun; 24(2):414-422.
107. Talcott WJ, Miccio JA, **Park HS**, White AA, Kozono DE, Singer L, Sands JM, Sholl LM, Detterbeck FC, Mak RH, Decker RH, Kann BH. Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ. *Lung Cancer* 2021 Jul; 157:17-20.
108. Xiao C, Miller AH, Peng G, Levine ME, Conneely KN, Zhao H, Eldridge RC, Wommack EC, Jeon S, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, **Park HS**, Irwin ML, Ferrucci LM, Ulrich B, Qian DC, Beitler JJ, Bruner DW. Association of epigenetic age acceleration with risk factors, survival, and quality of life in patients with head and neck cancer. *Int J Radiat Oncol Biol Phys* 2021 Sep; 111(1):157-167.
109. Talcott WJ, Yu JB, Gross CP, **Park HS**. Social connectedness among Medicare beneficiaries following the onset of the COVID-19 pandemic. *JAMA Intern Med* 2021 Sep; 181(9):1245-1248.
110. Liu Y, Cheng Y, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, Lou D, Yu H, Wang S, Qin H, Li X, Hamaji M, **Park HS**. Effect of prior thoracic radiotherapy on prognosis in relapsed SCLC patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial. *Transl Lung Cancer Res* 2021 Sep; 10(9):3793-3806.
111. Leapman MS, Wang R, **Park HS**, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of new risk stratification technologies within U.S. hospital referral regions and association with prostate cancer management. *JAMA Netw Open* 2021 Oct; 4(10):e2128646.
112. Metzger AL, Kusi Appiah A, Wright CM, Jairam V, Amini A, **Park HS**, Welsh JW, Thomas CR, Verma V, Ludmir EB. Financial relationships between industry and principal investigators of United States cooperative group randomized cancer clinical trials. *Int J Cancer* 2021 Nov; 149(9):1683-1690.
113. Jairam V, Pasha S, Soulos PR, Gross CP, Yu JB, **Park HS**, Decker RH. Post-operative radiation therapy for non-small cell lung cancer: a comparison of radiation therapy techniques. *Lung Cancer* 2021 Nov; 161:171-179.
114. Leapman MS, Wang R, **Park HS**, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in PSA testing relative to the revised U.S. Preventive Services Task Force recommendation on prostate cancer screening. *JAMA Oncol* 2021 Nov; e215143.

115. Li JY, **Park HS**, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate risk, early-stage endometrial cancer following vaginal brachytherapy. *Gynecol Oncol* 2021 Dec; 163(3):557-562.
116. Zaorsky NG, Wang X, Garrett S, Lehrer E, Lin C, Zhang Y, DeGraff DJ, Spratt DE, Trifiletti DM, Kishan AU, Showalter TN, **Park HS**, Yang TJ, Chinchilli VM, Wang M. Pan-cancer analysis of prognostic metastatic phenotypes. *Int J Cancer* 2022 Jan; 150(1):132-141.
117. Saeed NA, Jin L, Sasse AW, Amini A, Verma V, Lester-Coll NH, Chen PH, Decker RH, **Park HS**. Hypofractionated vs. standard radiotherapy for locally advanced limited-stage small cell lung cancer. *J Thorac Dis* 2022 Feb; 14(2):306-320.
118. Diamond BH, Verma N, Shukla UC, **Park HS**, Koffer PP. Consolidative thoracic radiotherapy after first-line chemotherapy and immunotherapy in extensive-stage small cell lung cancer: a multi-institutional case series. *Adv Radiat Oncol* 2022 Mar-Apr; 7(2):100883.
119. Buck M, Giraldi E, Demkowicz P, **Park HS**, An Y, Kann BH, Yu JB, Sprenkle PC, Kim IY, Leapman MS. Facility-level variation in use of locoregional therapy for metastatic prostate cancer. *Urol Pract* 2022 Mar; 9(2):140-149.
120. Raju SC, Peters GW, Decker RH, **Park HS**. Clinical outcomes and safety profile in the treatment of synchronous non-metastatic lung tumors with stereotactic body radiotherapy. *Pract Radiat Oncol* 2022 Mar-Apr; 12(2):e110-e116.
121. Haque W, Singh A, **Park HS**, Teh BS, Butler EB, Zeng M, Lin SH, Welsh JW, Chang JY, Verma V. Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. *Acta Oncol* 2022 Apr; 61(4):403-408.
122. Gao S, Jin L, Moliterno J, Corbin ZA, Bindra RS, Contessa JN, Yu JB, **Park HS**. Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma. *J Neurosurg* 2022 Jul; 138(3):610-620.
123. Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, **Park HS**, Goldberg SB, Boffa DJ. Immunotherapy after chemotherapy and radiation for clinical stage III lung cancer. *JAMA Netw Open* 2022 Aug; 5(8):e2224478.
124. Lee V, An Y, **Park HS**, Yu JB, Kim SP, Jairam V. Emergency department visits for radiation cystitis among patients with a prostate cancer history. *BJU Int* 2022 Aug; 130(2):208-216.
125. Jairam V, **Park HS**, Yu JB, Bindra RS, Contessa JN, Jethwa KR. Practice patterns related to mitigation of neurocognitive decline in patients receiving whole-brain radiation therapy. *Adv Radiat Oncol* 2022 Jul-Aug; 7(4):100949.
126. King ALO, Lee V, Mirza FN, Jairam V, Yang DX, Yu JB, **Park HS**, Girardi M, Wilson LD, An Y. Factors associated with in-hospital mortality in mycosis fungoides patients - a multivariable analysis. *Cureus* 2022 Aug; 14(8):e28043.
127. Tchelebi LT, Shen B, Wang M, Potters L, Herman J, Boffa D, Segel J, **Park HS**, Zaorsky NG. Non-adherence to multi-modality cancer treatment guidelines in the United States. *Adv Radiat Oncol* 2022 Sep-Oct; 7(5):100938.
128. Tran JH, Mhango G, **Park HS**, Marshall DC, Rosenzweig KE, Wang QW, Wisnivesky JP, Veluswamy RR. Outcomes following SBRT vs. IMRT and 3DCRT for older patients with stage IIA node-negative non-small cell lung cancer >5 cm. *Clin Lung Cancer* 2023 Jan; 24(1):e9-e18.
129. Saeed NA, Jin L, Amini A, Verma V, Lester-Coll NH, Chen PH, Decker RH, **Park HS**. Utilization and survival impact of hypofractionated radiotherapy in stage I non-small cell lung cancer. *Am J Clin Oncol* 2023 Feb; 46(2):66-72.
130. Qian DC, Ulrich BC, Peng G, Zhao H, Conneely KN, Miller AH, Bruner DW, Eldridge RC, Wommack EC, Higgins KA, Shin DM, Saba NF, Smith AK, Burtress BA, **Park HS**, Stokes WA, Beitler JJ, Xiao C. Outcomes stratification of head and neck cancer using pre- and post-treatment DNA methylation from peripheral blood. *Int J Radiat Oncol Biol Phys* 2023 Apr; 115(5):1217-1228.
131. Peters GW, Talcott W, Peters NV, Dhanasopon A, Lacy J, Cecchini M, Kortmansky J, Stein S, Kunz PL, Lattanzi S, **Park HS**, Boffa D, Johung KL, Jethwa KR. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally advanced esophageal cancer. *J Gastrointest Oncol* 2023 Jun; 14(3):1181-1192.
132. Wu Y, Guo Z, Meng L, Fan R, Gridelli C, **Park HS**, Cao Y, Wang LA retrospective comparative cohort study: concurrent versus consolidative immunotherapy with chemoradiotherapy in EGFR- or

- ALK-negative unresectable stage III non-small cell lung cancer. *Transl Lung Cancer Res* 2023 Nov; 12(11):2209-2218.
133. Jairam V, Soulos PR, KC M, Gross CP, Slotman BJ, Chiang AC, **Park HS**. Differential impact of consolidative thoracic radiotherapy in extensive-stage small cell lung cancer based on sex. *Adv Radiat Oncol* 2023 Dec; 9(4):101413.
134. Baum LVM, KC M, Soulos PR, Jeffery MM, Ruddy KJ, Lerro CC, Lee H, Graham DJ, Rivera DR, Leapman MS, Jairam V, Dinan MA, Gross CP, **Park HS**. Trends in new and persistent opioid use in older adults with and without cancer. *J Natl Cancer Inst* 2024 Feb; 116(2):316-323. Named as “Editor’s Choice.”
135. Udelsman BV, Canavan ME, Zhan PL, Ely S, **Park HS**, Boffa DJ, Mase VJ. Overall survival in low-comorbidity patients with stage I non-small cell lung cancer who chose stereotactic body radiotherapy compared to surgery. *J Thorac Cardiovasc Surg* 2024 Mar; 167(3):822-833.e7.
136. Verma N, Laird JH, Moore N, Hayman TJ, Housri N, Peters GW, Knowlton CA, Jairam V, Campbell AM, **Park HS**. Radioresistant pulmonary oligometastatic and oligoprogressive lesions from non-lung primaries: impact of histology and dose-fractionation on local control following radiotherapy. *Adv Radiat Oncol* 2024 Mar; 9(6):101500.
137. Sasse A, Oh P, Saeed N, Yang DX, Hayman TJ, Knowlton CA, Peters GW, Campbell A, Laird JH, Housri N, **Park HS**. Dose-volume predictors of radiation pneumonitis following thoracic hypofractionated radiotherapy. *Pract Radiat Oncol* 2024 Mar-Apr; 14(2):e97-e104.
138. Malik D, Jacobs D, Fereydooni S, **Park HS**, Mehra S. Patterns of care for T1 glottic squamous cell carcinomas from 2004-2020. *Laryngoscope* 2024 Aug; 134(8):3633-3644.
139. Mell LK, Torres-Saavedra PA, Wong S, Kish JA, Chang SS, Jordan R, Liu T, Truong MT, Winquist EW, Takiar V, Wise-Draper T, Robbins J, Rodriguez CP, Awan MJ, Beadle BM, Henson C, Narayan S, Spencer SA, Powell SF, Dunlap N, Sacco AG, Hu KS, **Park HS**, Bauman JE, Harris J, Yom SS, Le QT. Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): A randomised, open-label phase II/III trial. *Lancet Oncol* 2024 Dec; 25(12):1576-1588.
140. Fish A, **Park HS**, Knight E, Knowlton CA, Madoff DC. Percutaneous cryoablation of non-small cell lung cancer in patients with recurrence after stereotactic body radiation therapy. *Cardiovasc Intervent Radiol* 2025 May; 48(5):626-632.
141. Lee V, Moore NS, Doyle J, Hicks D, Oh P, Bodofsky S, Hossain S, Patel AA, Aneja S, Homer R, **Park HS**. Prediction of lymph node metastasis in non-small cell lung carcinoma using primary tumor somatic mutation data. *JCO Clin Cancer Inform* 2025 Jun; 9:e2400303.
142. Jairam V, Lindsay ME, Soulos PR, Gross CP, Prsic EH, Baum LVM, **Park HS**. Temporal trends in opioid use and associated outcomes for patients living with advanced cancer. *J Pain Symptom Manage* 2025 Sep; 70(3):230-238.e7.
143. Baum LVM, Soulos PR, KC M, Jeffery MM, Ruddy KJ, Lerro CC, Lee H, Graham DJ, Rivera DR, Liberatore M, Leapman MS, Jairam V, Dinan MA, Gross CP, **Park HS**. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. *Cancer* 2025 Oct; 131(19):e70027.
144. Ashraf MR, Pham D, Bal G, Chen H, **Park HS**, Watkins T, Cai B, Badiyan SN, Vitzthum LK, Loo BW Jr, Surucu M. Multi-institutional verification of a novel predictor (volume-scaled SUVmax) for successful biology-guided radiotherapy delivery of small targets. *Cancers* 2025 Nov; 17(22):3645.
145. Adib E, Nassar AH, Lee KN, Fusco F, Crowley F, Baena J, Worth JE, Abi Jaoude J, Addeo A, Bou Farhat E, Rakae M, Amini A, Lambden J, Rost M, Bolnykh I, Aboubakar Nana F, Aujayeb A, Cortellini A, Newsom-Davis TE, Camidge DR, Vitzthum LK, Cappuzzo F, Marron TU, Lanuti M, Gainor JF, Kwiatkowski DJ, **Park HS**, Owen D, Keane FF. Definitive radiotherapy with or without chemotherapy following chemo-immunotherapy in stage II-III NSCLC: an international multicenter study. *JTO Clin Res Rep* 2025 Dec; 7(4):100949.
146. Rybkin A, Lee V, Young MR, Eskander A, Burtneess BA, **Park HS**, Husain ZA. Evaluation of a novel prognostic system for surgically resected oral cavity carcinoma. *Head Neck* 2026 Jan; 48(1):175-183.
147. Poghosyan H, Sarkar S, Zaidi M, Sather P, Duan R, **Park HS**. Perceived racial discrimination in healthcare settings and lung cancer screening use. *Nurs Res* 2026 May-Jun; 75(3):167-174.

148. Ninia JG, Verma N, Long JB, Laird JH, Hicks DF, Hayman TJ, Knowlton CA, Campbell AM, Housri N, Peters GW, Al Feghali KA, de Jong D, Chiang AC, **Park HS**. Consolidative radiotherapy for extensive-stage small cell lung cancer: outcomes based on completeness of consolidation and oligometastatic state. *Clin Lung Cancer* 2026 May; 27(4):14-23.
149. Becht K, Lindsay ME, Soulos PR, Singh C, Hansen JE, An Y, Aneja S, Goldberg SB, Chiang VL, **Park HS**. Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancer. *J Neurooncol* 2026 May; 177(3):151.
150. Ziaks TJ, Oh P, Hicks D, Laird JH, Verma N, Knowlton CA, Hayman TJ, **Park HS**. Sequencing of stereotactic body radiation therapy and chemotherapy in stage I small cell lung cancer: practice patterns and outcomes. *Adv Radiat Oncol* 2026; Accepted.

Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

151. **Park HS**, Chiang VL, Knisely JP, Raldow AC, Yu JB. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update. *Expert Rev Anticancer Ther* 2011 Nov; 11(11):1731-1738.
152. **Park HS**, Lloyd S, Decker RH, Wilson LD, Yu JB. Overview of the Surveillance, Epidemiology, and End Results database: evolution, data variables, and quality assurance. *Curr Probl Cancer* 2012 Jul; 36(4):183-190.
153. Lloyd S, **Park HS**, Decker RH, Wilson LD, Yu JB. Using the Surveillance, Epidemiology, and End Results database to investigate rare cancers, second malignancies, and trends in epidemiology, treatment, and outcomes. *Curr Probl Cancer* 2012 Jul; 36(4):191-199.
154. Lloyd S, **Park HS**, Wilson LD, Decker RH, Yu JB. Prediction models, nomograms, and staging validation with the Surveillance, Epidemiology, and End Results database. *Curr Probl Cancer* 2012 Jul; 36(4):200-207.
155. Yu JB, Lloyd S, Decker RH, Wilson LD, **Park HS**. Comparative effectiveness analysis and the Surveillance, Epidemiology, and End Results database. *Curr Probl Cancer* 2012 Jul; 36(4):208-215.
156. **Park HS**, Lloyd S, Decker RH, Wilson LD, Yu JB. Limitations and biases of the Surveillance, Epidemiology, and End Results database. *Curr Probl Cancer* 2012 Jul; 36(4):216-224.
157. **Park HS**, Decker RH. Disparities in radiation therapy delivery: current evidence and future directions in head and neck cancer. *Cancers Head Neck* 2016 Jun; 1(5):1-5.
158. Jairam V, **Park HS**. Strengths and limitations of large databases in lung cancer radiation oncology research. *Transl Lung Cancer Res* 2019 Sep; 8(Suppl 2):S172-S183.
159. Jairam V, **Park HS**, Decker RH. Local ablative therapies for oligometastatic and oligoprogressive non-small cell lung cancer. *Cancer J* 2020 Mar-Apr; 26(2):129-136.
160. Hayman TJ, Bhatia AK, Jethwa KR, Young MR, **Park HS**. Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review. *Transl Cancer Res* 2021 May;10(5):2571-2585.
161. Detterbeck FC, Blasberg JD, Woodard GA, Decker RH, Kumbasar U, **Park HS**, Mase VJ Jr, Bade BC, Li AX, Brandt WS, Madoff DC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation - Part 1: a guide to decision-making. *J Thorac Dis* 2022 Jun; 14(6):2340-2356.
162. Detterbeck FC, Mase VJ Jr, Li AX, Kumbasar U, Bade BC, **Park HS**, Decker RH, Madoff DC, Woodard GA, Brandt WS, Blasberg JD. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation - Part 2: systematic review of evidence regarding resection extent in generally healthy patients. *J Thorac Dis* 2022 Jun; 14(6):2357-2386.
163. Bade BC, Blasberg JD, Mase VJ Jr, Kumbasar U, Li AX, **Park HS**, Decker RH, Madoff DC, Brandt WS, Woodard GA, Detterbeck FC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation - Part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors. *J Thorac Dis* 2022 Jun; 14(6):2387-2411.
164. **Park HS**, Detterbeck FC, Madoff DC, Bade BC, Kumbasar U, Mase VJ Jr, Li AX, Blasberg JD, Woodard GA, Brandt WS, Decker RH. A guide for managing patients with stage I NSCLC: deciding

between lobectomy, segmentectomy, wedge, SBRT and ablation - Part 4: systematic review of evidence involving SBRT and ablation. *J Thorac Dis* 2022 Jun; 14(6):2412-2436.

165. Reid E, Suneja G, Al-Rohil R, Ambinder RF, Ard K, Baiocchi R, Carchman E, Christensen S, Crysler OV, Goyal G, Gupta N, Henry DH, Jones A, Klopp A, LaCasce AS, Lin C, Menon MP, Morgan D, Nathwani N, **Park HS**, Ratner L, Rizza S, Sanchez J, Taylor J, Timmerman J, Tomlinson B, Wang CJ, Yeldandi AV, Schoenfeld R, Freedman-Cass D. Cancer in people with HIV. Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
166. Reid E, Suneja G, Al-Rohil R, Ambinder RF, Ard K, Baiocchi R, Carchman E, Christensen S, Crysler OV, Goyal G, Gupta N, Henry DH, Jones A, Klopp A, LaCasce AS, Lin C, Menon MP, Morgan D, Nathwani N, **Park HS**, Ratner L, Rizza S, Sanchez J, Taylor J, Timmerman J, Tomlinson B, Wang CJ, Yeldandi AV, Schoenfeld R, Freedman-Cass D. Kaposi sarcoma. Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
167. Chun SG, Rimner A, Amini A, Chang JY, Donington J, Edelman MJ, Geng Y, Gubens MA, Higgins KA, Iyengar P, Movsas B, Ning MS, **Park HS**, Rodrigues G, Wolf A, Simone CB II. American Radium Society Appropriate Use Criteria: Radiation therapy in the multidisciplinary management of thymic carcinoma. *JAMA Oncol* 2023 Jul; 9(7):971-980.
168. Gross AJ, Pisano CE, Khunsriraksakul C, Spratt DE, **Park HS**, Sun Y, Wang M, Zaorsky NG. Real-World Data: Applications and Relevance to Cancer Clinical Trials. *Semin Radiat Oncol* 2023 Oct; 33(4):374-385.
169. Reid E, Suneja G, Al-Rohil R, Ambinder RF, Ard K, Baiocchi R, Campbell T, Carchman E, Christensen S, Dickson M, Goyal G, Gupta N, Henry DH, Jones A, Klopp A, LaCasce AS, Lin C, Maurer T, Menon MP, Morgan D, Moxley K, Nathwani N, Paragh G, **Park HS**, Patel K, Ratner L, Rizza S, Sanchez J, Taylor J, Timmerman J, Tomlinson B, Wang CJ, Yeldandi AV, Schoenfeld R, Freedman-Cass D. Cancer in people with HIV. Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
170. Reid E, Suneja G, Al-Rohil R, Ambinder RF, Ard K, Baiocchi R, Campbell T, Carchman E, Christensen S, Dickson M, Goyal G, Gupta N, Henry DH, Jones A, Klopp A, LaCasce AS, Lin C, Maurer T, Menon MP, Morgan D, Moxley K, Nathwani N, Paragh G, **Park HS**, Patel K, Ratner L, Rizza S, Sanchez J, Taylor J, Timmerman J, Tomlinson B, Wang CJ, Yeldandi AV, Schoenfeld R, Freedman-Cass D. Kaposi sarcoma. Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
171. Rodrigues G, Higgins KA, Rimner A, Amini A, Chang JY, Chun SG, Donington J, Edelman MJ, Gubens MA, Iyengar P, Movsas B, Ning MS, **Park HS**, Wolf A, Simone CB II. American Radium Society Appropriate Use Criteria for unresectable locally advanced non-small cell lung cancer. *JAMA Oncol* 2024 Jun; 10(6):799-806.
172. Detterbeck FC, Woodard GA, Bader AS, Dacic S, Grant MJ, **Park HS**, Tanoue LT. The proposed 9th edition TNM classification of lung cancer. *Chest* 2024 Oct; 166(4):882-89.
173. **Park HS**, Rimner A, Amini A, Chang JY, Chun SG, Donington J, Edelman MJ, Gubens MA, Higgins KA, Iyengar P, Juloori A, Movsas B, Nemeth Z, Ning MS, Rodrigues G, Wolf A, Simone CB II. Executive summary of the American Radium Society® (ARS) Appropriateness Use Criteria (AUC) for non-small cell lung cancer in a central/ultra-central location: systematic review and guidelines. *J Thorac Oncol* 2024 Dec; 19(12):1640-1653.
174. Amini A, Zaha VG, Hamad E, Woodard PK, Rimner A, Chang JY, Chun SG, Donington J, Edelman MJ, Gubens MA, Higgins KA, Iyengar P, Juloori A, Movsas B, Ning MS, **Park HS**, Rodrigues G, Wolf A, Simone CB II. American Radium Society® Appropriate Use Criteria on cardiac toxicity prevention and management after thoracic radiotherapy. *J Thorac Oncol* 2024 Dec; 19(12):1654-1667.
175. Reid E, Suneja G, Al-Rohil R, Alexiev B, Ambinder RF, Ard K, Baiocchi R, Campbell T, Carchman E, Dickson E, Eschenauer G, Goyal G, Gupta NK, Henry DH, Jones A, Kimani S, Klopp A, LaCasce AS, Lin C, Maurer T, Menon MP, Morgan D, Nathwani N, Palm D, Paragh G, **Park HS**, Ratner L, Rizza S, Sanchez J, Schorge J, Timmerman J, Wang CJ, Freedman-Cass D, Nguyen J, Schonfeld R. Cancer in people with HIV. Version 1.2024, NCCN Clinical Practice Guidelines in Oncology.
176. Reid E, Suneja G, Al-Rohil R, Alexiev B, Ambinder RF, Ard K, Baiocchi R, Campbell T, Carchman E, Dickson E, Eschenauer G, Goyal G, Gupta NK, Henry DH, Jones A, Kimani S, Klopp A, LaCasce

AS, Lin C, Maurer T, Menon MP, Morgan D, Nathwani N, Palm D, Paragh G, **Park HS**, Ratner L, Rizza S, Sanchez J, Schorge J, Timmerman J, Wang CJ, Freedman-Cass D, Nguyen J, Schonfeld R. Kaposi Sarcoma. Version 1.2024, NCCN Clinical Practice Guidelines in Oncology.

177. Lehrer EJ, Khunsriraksakul C, Garrett S, Trifeletti DM, Sheehan JP, Guckenberger M, Louie AV, Siva S, Ost P, Goodman KA, Dawson LA, Tchelebi LT, Yang JT, Showalter TN, **Park HS**, Spratt DE, Kishan AU, Gupta GP, Shah C, Fanti S, Calais J, Wang M, Schmitz K, Liu D, Abraham JA, Dess RT, Buvat I, Solomon BJ, Zaorsky NG. Future directions in the evaluation and management of newly diagnosed metastatic cancer. *Crit Rev Oncol Hematol* 2025 Apr; 208:104631.
178. Kim SY, **Park HS**, Chiang AC. Small cell lung cancer: a review. *JAMA* 2025 Jun; 333(21):1906-1917.
179. Han DY, Chen H, Zhong W, Lee MY, **Park HS**, Chang YH, Chen Z, Carlson DJ. Positron emission tomography-guided radiation therapy: an overview of the RefleXion SCINTIX biology-guided platform. *J Radiosurg SBRT* 2026 Feb; 10(1-2):13-21.

Peer-Reviewed Educational Materials

180. Mokhtech M, Talcott WJ, **Park HS**. Creating the in-person experience on a virtual platform. *Oncology Fellows* 2020 Dec; 12(4).
181. Schiff JP, Park J, Badiyan SN, Cai B, **Park HS**, Amini A, Vitzthum LK, McCall N, Chang EL, Ye. Biology-guided radiotherapy: a new frontier in PET-guided radiation oncology. *Clin Nucl Med Open* 2025 Sep; 2(3):e0027.

Peer-Reviewed Case Reports and Technical Notes

182. van Dams R, **Park HS**, Alomari AK, Ricciardi AS, Rao H, McNamara J, DiLuna ML, Bindra RS. Adjuvant hypofractionated partial-brain radiation therapy for pediatric Ewing sarcoma brain metastases: a case report and literature review. *J Neurosurg Pediatr* 2016 Apr; 17(4):434-438.
183. Hong CS, Partovi E, Clune J, Huttner A, **Park HS**, Omay SB. Genomic characterization of radiation-induced intracranial undifferentiated pleomorphic sarcoma. *Case Rep Genet* 2021 Mar; 5586072.

Books

184. Lung Cancer: Modern Multidisciplinary Management, ed. **H.S. Park**. InTechOpen, 2021; pp. 1-212.

Chapters

185. **Park HS**, Yu JB, Knisely JP, Chiang VL. Outcomes following Gamma Knife for metastases. In Gamma Knife Radiosurgery, ed. D. Mathieu, InTechOpen, 2011, pp. 3-28.
186. Chang E, Zaorsky NG, **Park HS**. Systematic reviews and meta-analyses. In: Principles of Clinical Cancer Research, ed. L.K. Mell, P.T. Tran, J.B. Yu, and Q. Zhang. Demos Medical 2018; 521-541.
187. Trifeletti DM, Zaorsky NG, **Park HS**. Head and neck cancers. In: Absolute Clinical Radiation Oncology Review, ed. D.M. Trifeletti and N.G. Zaorsky. Springer 2018; 133-196.
188. **Park HS**, Young MR. Nasopharynx cancer. In: Pocket Guide to Radiation Oncology, 2nd edition, ed. D. Chamberlain, J.B. Yu, and R.H. Decker. Springer 2020; 37-40.
189. **Park HS**, Young MR. Nasal cavity and paranasal sinus cancer. In: Pocket Guide to Radiation Oncology, 2nd edition, ed. D. Chamberlain, J.B. Yu, and R.H. Decker. Springer 2020; 41-44.
190. **Park HS**, Young MR. Oropharynx cancer. In: Pocket Guide to Radiation Oncology, 2nd edition, ed. D. Chamberlain, J.B. Yu, and R.H. Decker. Springer 2020; 45-49.
191. Young MR, **Park HS**. Oral cavity and lip cancer. In: Pocket Guide to Radiation Oncology, 2nd edition, ed. D. Chamberlain, J.B. Yu, and R.H. Decker. Springer 2020; 51-55.
192. Young MR, **Park HS**. Major salivary gland cancer. In: Pocket Guide to Radiation Oncology, 2nd edition, ed. D. Chamberlain, J.B. Yu, and R.H. Decker. Springer 2020; 57-60.
193. **Park HS**, Young MR. Larynx and hypopharynx cancer. In: Pocket Guide to Radiation Oncology, 2nd edition, ed. D. Chamberlain, J.B. Yu, and R.H. Decker. Springer 2020; 61-65.
194. **Park HS**, Peter PR, Young MR. Thyroid cancer. In: Pocket Guide to Radiation Oncology, 2nd edition, ed. D. Chamberlain, J.B. Yu, and R.H. Decker. Springer 2020; 67-70.
195. Young MR, **Park HS**. Occult primary cancer of the head and neck. In: Pocket Guide to Radiation Oncology, 2nd edition, ed. D. Chamberlain, J.B. Yu, and R.H. Decker. Springer 2020; 71-77.

196. **Park HS.** Recent progress in lung cancer treatment: the value of multiple perspectives. In Lung Cancer: Modern Multidisciplinary Management, ed. **H.S. Park**, InTechOpen, 2021; pp. 3-7.
197. Crosby T, Laird JH, **Park HS**, McWhorter A. Early laryngeal cancer. In: Bailey's Head and Neck Surgery: Otolaryngology, 6th edition, ed. C.A. Rosen, S. Gray, P. Ha, C. Limb, S. Park, and G. Richter. LWW, 2022; pp. 2252-2281.
198. Venkatesulu BP, Girdhar P, **Park HS**, Mendenhall WM, Verma V. Advances in radiation: ion therapy and advanced techniques. In: Multidisciplinary Management of Head and Neck Cancer: Contemporary Applications and Techniques, ed. R.A. Chandra and R.J. Li. Springer, 2022; pp. 45-59.
199. Laird JH, Roberts KB, Decker RH, **Park HS**. Radiation pneumonitis. In: Fishman's Pulmonary Diseases and Disorders, 6th edition, ed. M. Grippi, D. Antin-Ozerkis, C. Dela Cruz, R. Kotloff, C. Kotton, A. Pack. McGraw-Hill Medical, 2022; pp. 966-986.
200. Laird JH, Deng J, Sinha S, Chin RK, Yom SS, **Park HS**. Targeted radiation for head and neck cancer: specificity and de-escalation. In: Essential Head and Neck Oncology and Surgery: KJ Lee Essential Medicine Series, ed. M. St. John and B. Judson. Nova Science Publishers, 2023; pp. 453-468.
201. Morgensztern D, Detterbeck F, Drilon A, Goldberg SB, **Park HS**, Politi K, Schalper KA, Tanoue LT, Herbst RS. Non-small cell lung cancer. In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 12th edition, ed. V.T. DeVita, T.S. Lawrence, S.A. Rosenberg. Wolters Kluwer, 2023; pp. 349-390.
202. Chiang JM, Peter PR, **Park HS**. Thyroid cancer. In: Pocket Guide to Radiation Oncology, 3rd edition, ed. D. Chamberlain and J.B. Yu. Springer 2026; Accepted.
203. Park J, Schiff JP, Chen H, Matani H, **Park HS**. Biology-guided radiation therapy. In: Pocket Guide to Radiation Oncology, 3rd edition, ed. D. Chamberlain and J.B. Yu. Springer 2026; Accepted.

Commentaries, Editorials, and Letters

204. Lester-Coll NH, **Park HS**, Gross CP, Yu JB. Author reply. *Urology* 2016 Oct; 96:134-135.
205. **Park HS**, Ma S, Wilson LD, Moran MS. In regards to Vaidya et al. *Int J Radiat Oncol Biol Phys* 2016 Nov; 96(3):706-707.
206. Tchouta LN, **Park HS**, Boffa DJ, Blasburg JD, Detterbeck FC, Kim AW. Response. *Chest* 2017 Apr; 151(4):942-943.
207. Bledsoe TJ, **Park HS**, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Response. *J Natl Cancer Inst* 2018 Apr; 110(4):433-434.
208. Leapman MS, Wang R, **Park HS**, Yu JB, Weinreb JC, Gross CP, Ma X. Author Reply. *Urology* 2019 Feb; 124:106.
209. **Park HS**. Cancer clinical trial enrollment: OK doc, but what's in it for me? *J Natl Compr Cancer Netw* 2019 Nov; 17(1):1404-1405.
210. **Park HS**, Yu JB. Proton-based chemoradiation: what level of evidence is necessary to justify its widespread use? *JAMA Oncol* 2020 Feb; 6(2):246-247.
211. **Park HS**. Leveraging surgical case volume in improving cancer care outcomes: where do we go from here? *J Natl Compr Cancer Netw* 2021 May; 19(5):577-579.
212. Mattes MD, Suneja G, Haffty BG, Takita C, Katz MS, Ohri N, Deville C, Siker ML, **Park HS**. Overcoming barriers to radiation oncology access in low-resource settings in the United States. *Adv Radiat Oncol* 2021 Sep; 6(6):100802.
213. Johung KL, **Park HS**. Less is more: lower doses for intermediate-term oropharyngeal control. *Int J Radiat Oncol Biol Phys* 2022 Mar; 112(3):585.
214. Jairam V, Pasha S, Soulos PR, Gross CP, Yu JB, **Park HS**, Decker RH. A reply to "Randomized controlled clinical trial is needed for toxicity of IMRT vs 3D-CRT in PORT for LA-NSCLC." *Lung Cancer* 2022 Jun; 168:84-85.
215. Lester-Coll NH, **Park HS**. Stereotactic body radiotherapy in locally advanced non-small cell lung cancer – is this the future? *JAMA Oncol* 2024 Mar; 10(3):360-361.
216. Amini A, **Park HS**. Fibrosis or recurrence after lung stereotactic body radiation therapy: a proposed decision tree. *Pract Radiat Oncol* 2024 Nov-Dec; 14(6):e467-e469.
217. Rybkin A, Bhatia A, **Park HS**. Redefining systemic therapy timing in nasopharyngeal cancer – before, during, or after radiation. *JAMA Oncol* 2025 Sep; 11(9):967-969.

218. Shen JL, **Park HS**. Seize the thy-moment: go big or go home. *Int J Radiat Oncol Biol Phys* 2025 Sep; 123(1):13.
219. Rybkin A, Young MR, **Park HS**. Will adaptive radiation therapy be the new state-of-the-ART in head and neck cancer? *J Natl Cancer Inst* 2026 Jan; 118(1):1-3.
220. Piper-Vallillo AJ, **Park HS**. The emerging role for induction chemoimmunotherapy in unresectable stage III NSCLC: a promising approach in need of a definitive phase III trial. *Lung Cancer* 2026 Apr; 214:109349.
221. Ninia J, **Park HS**. Breathe easy: tread lightly when managing nodal oligoprogression. *Int J Radiat Oncol Biol Phys* 2026 May; 125(1):17-18.